Emopamil binding protein inhibitors and uses thereof
By combining EBP inhibitors of specific compounds with drug carriers, the problem of poor inhibition of EBP function in the prior art is solved, and the effect of remyelination and cancer treatment is improved.
Patent Information
- Application Number
- CN202380026612.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-24
- Filing Date
- 2023-01-23
- Publication Date
- 2024-12-06
AI Technical Summary
Existing treatments are difficult to effectively inhibit the function of emopam binding protein (EBP), resulting in poor myelination and treatment of certain cancers.
An EBP inhibitor and a pharmaceutically acceptable salt comprising a specific compound are provided for in combination with a pharmaceutical carrier for the manufacture of pharmaceutical preparations for the treatment of EBP-mediated diseases by administering these compounds to a subject to inhibit EBP activity.
Effectively inhibit EBP activity, promote remyelination, is used to treat multiple sclerosis and other myelin-related diseases, and shows therapeutic potential in colorectal cancer.
Smart Images

Figure CN119095845A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of the filing date of U.S. Provisional Application No. 63 / 302,195, filed on January 24, 2022, under 35 U.S. Patent Act Section 119(e), the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present disclosure relates to inhibitors of emopamide binding protein (EBP) and pharmaceutically acceptable salts thereof, compositions of these compounds, methods for their preparation, their use in treating diseases, their use, optionally in combination with a pharmaceutically acceptable carrier, for the manufacture of pharmaceutical preparations, the use of pharmaceutical preparations in treating diseases, and methods for treating diseases, the methods comprising administering the EBP inhibitors to warm-blooded animals, especially humans. Background Art
[0004] Emopamil binding protein (EBP) is a Δ8-Δ7 sterol isomerase that isomerizes the double bond in the sterol molecule, moving the double bond from the 8-9 position to the 7-8 position. Specifically, during the biosynthesis of cholesterol, EBP converts zymostenol to 7-lathosterol, or converts zymostenol to dehydrolathosterol (Silve et al., 1996, J Biol Chem. 271 (37), 22434-22440). Studies have shown that the accumulation of 8-9 unsaturated sterols can activate oligodendrocyte formation and myelin regeneration (Hubler et al., 2019, Nature 560 (7718), 372-376).
[0005] Myelin is a lipid molecule that forms a protective layer (myelin sheath) around the axons of nerve cells and isolates axons. Demyelination or myelin-related diseases are the result of these myelin sheaths being damaged, degenerated or reduced in thickness. The loss of myelin sheaths can disrupt the electronic signals from the brain and may cause nerve damage, vision loss, numbness, muscle weakness, cognitive decline, motor function loss and other similar symptoms. In some diseases related to myelin such as multiple sclerosis, the subject's immune system will attack and decompose its own myelin sheath. The ability to repair and regenerate myelin sheaths is the key to treating these myelin-related diseases. Because EBP has the function of converting 8-9 sterols, its inhibition is a potential target for activating myelin regeneration, because its inhibition can lead to an increase in these 8-9 sterol starting materials (Theodoropoulous et al., 2020, J.Am.Chem.Soc., 142, (13), 6128-6138).
[0006] In addition to its role in myelin regeneration, EBP has also been shown to be a key enzyme in certain colorectal cancers as it can reduce essential lipids such as cholesterol (Theodoropoulous et al., 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
[0007] Therefore, there is a need for EBP inhibitors as potential therapeutic agents for treating diseases or conditions responsive to EBP inhibition. Summary of the invention
[0008] The present disclosure provides compounds that are EBP inhibitors. In a first aspect, the present disclosure relates to compounds having formula (I):
[0009]
[0010] or a pharmaceutically acceptable salt thereof, wherein:
[0011] R 1 and R 2 Each independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, Het, -Z-Het and ZC 3-8 Cycloalkyl, wherein the C 1-6 Alkyl, C 3-8 Cycloalkyl and Het are each optionally substituted by one or more R 4 Replace, provided that R 1 and R 2 At least one of is not H; or
[0012] R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4 substituted 4- to 10-membered heterocyclyl;
[0013] Z is C optionally substituted by one or more halogen groups 1-4 alkyl;
[0014] Het is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bicyclic heterocyclyl, each of which is optionally replaced by R 4 replace;
[0015] R 3 is phenyl, 5 or 6-membered monocyclic heteroaryl or 9 or 10-membered bicyclic heteroaryl, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl and 9 or 10-membered bicyclic heteroaryl are each optionally substituted by one or more substituents R 5 replace;
[0016] R 4 Each occurrence is independently C1-6 Alkyl, halide and -OR 4a , wherein the C 1-6 The alkyl group is optionally replaced by -OR 4a replace;
[0017] R 4a H, C 1-6 Alkyl or C 1-6 Haloalkyl;
[0018] R 5 Each occurrence is independently halo, -OR 5a , C 1-6 Alkyl, C 3-6 cycloalkyl, 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl or phenyl, wherein the C 1-6 Alkyl, C 3-6 The cycloalkyl and 5- to 6-membered monocyclic heteroaryl groups are each optionally substituted with one or more halogen, C 1-4 Alkyl or -OR 5a replace;
[0019] or two R 5 Together with its intervening atoms, it forms optionally one or more independently selected from C 1-6 Alkyl, oxo, halo, and –OR 5a R 6 substituted 5- to 7-membered heterocyclic ring;
[0020] R 5a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group;
[0021] R 7 H or OR 7a ;
[0022] R 7a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group;
[0023] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
[0024] In yet another aspect, the present disclosure provides a method of treating a disease or condition responsive to inhibition of EBP in a subject, comprising administering to the subject an effective amount of at least one compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method for treating multiple sclerosis. In some embodiments, the present disclosure provides a method for promoting myelination in a subject with a myelin-related disorder.
[0025] Another aspect of the present disclosure relates to the use of at least one compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or condition responsive to inhibition of EBP. Also provided is a compound described herein or a pharmaceutically acceptable salt thereof for use in treating a disease or condition responsive to inhibition of EBP. DETAILED DESCRIPTION
[0026] The present disclosure provides compounds and pharmaceutical compositions thereof, which can be used to treat diseases or conditions resulting from the mediation of EBP function / activity, such as multiple sclerosis or other myelin-related conditions. In some embodiments, the compounds of the present disclosure are EBP inhibitors.
[0027] Compounds and compositions
[0028] In a first embodiment, the present disclosure provides a compound of formula (I):
[0029]
[0030] or a pharmaceutically acceptable salt thereof, wherein:
[0031] R 1 and R 2 Each independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, Het, -Z-Het, wherein the C 1-6 Alkyl, C 3-8 Cycloalkyl and Het are each optionally substituted by one or more R 4 Replace, provided that R 1 and R 2 At least one of is not H; or
[0032] R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4 substituted 4- to 10-membered heterocyclyl;
[0033] Z is C optionally substituted by one or more halogen groups 1-4 alkyl;
[0034] Het is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bicyclic heterocyclyl, each of which is optionally replaced by R 4 replace;
[0035] R 3 is phenyl, 5 or 6-membered monocyclic heteroaryl or 9 or 10-membered bicyclic heteroaryl, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl and 9 or 10-membered bicyclic heteroaryl are each optionally substituted by one or more substituents R 5 replace;
[0036] R 4 Each occurrence is independently C 1-6 Alkyl, halide and -OR 4a ;
[0037] R 4a H, C 1-6 Alkyl or C 1-6 Haloalkyl;
[0038] R 5 Each occurrence is independently halo, -OR 5a , C 1-6 Alkyl, C 3-6 cycloalkyl, 4 to 7 membered monocyclic heterocyclic group or phenyl, wherein the C 1-6 Alkyl and C 3-6 The cycloalkyl groups are each optionally substituted with one or more halo, -OR 5a replace;
[0039] or two R 5 Together with its intervening atoms, it forms optionally one or more independently selected from C 1-6 Alkyl, oxo, halo, and –OR 5a R 6 substituted 5- to 7-membered heterocyclic ring;
[0040] R 5a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group;
[0041] R 7 H or OR 7a ;
[0042] R 7a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group;
[0043] In a second embodiment, the compounds of the present disclosure are of formula (II):
[0044]
[0045] or a pharmaceutically acceptable salt thereof; wherein the variables in formula (II) are as defined in the first aspect or the first embodiment above.
[0046] In a third embodiment, the compounds of the present disclosure are of formula (IIA) or (IIB):
[0047]
[0048] or a pharmaceutically acceptable salt thereof; wherein the variables in formula (IIA) or (IIB) are as defined above in the first aspect or the first or second embodiment.
[0049] In a fourth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, furanyl, oxadiazolyl, imidazopyridinyl, thienyl, thiazolyl, triazolyl and indolyl, each of which is optionally substituted by one to three R 5 and the remaining variables are as described in the first aspect or the first, second or third embodiment. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, furanyl, oxadiazolyl, imidazopyridinyl and thienyl, each of which is optionally substituted by one to three R 5 and the remaining variables are as described in the first aspect or the first, second or third embodiment.
[0050] In a fifth embodiment of the present disclosure, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0051]
[0052] Each of which is optionally replaced by one to three R 5 Replacement; or R 3 It is expressed by the following formula:
[0053]
[0054] Each of which is optionally replaced by one or two R 6 and the remaining variables are as described in the first aspect or the first, second, third or fourth embodiment or any alternative embodiment described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0055] Each of which is optionally replaced by one to three R 5 Replacement; or R 3 It is expressed by the following formula:
[0056]
[0057] Each of which is optionally replaced by one or two R 6 and the remainder of the variables are as described in the first aspect, or the first, second, third or fourth embodiment, or any alternative embodiments described therein.
[0058] In a sixth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl and pyridyl, each of which is optionally substituted by one to three R 5 and the remaining variables are as described in the fourth embodiment.
[0059] In a seventh embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0060] Each of which is optionally replaced by one or two R 5 Replacement; or R 3 It is expressed by the following formula:
[0061] Each of which is optionally replaced by one or two R 6 and the remaining variables are as described in the fifth embodiment.
[0062] In an eighth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0063]
[0064]
[0065] and the remaining variables are as described in the fifth embodiment. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0066] And the remaining variables are as described in the fifth embodiment.
[0067] In a ninth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0068]
[0069] And the remaining variables are as described in the fifth embodiment.
[0070] In a tenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, wherein R 5 Each occurrence is independently halo, -OR 5a , C 1-6 alkyl, a 4- to 7-membered monocyclic heterocyclic group or a phenyl group, wherein the C 1-6 The alkyl group is optionally replaced by -OR 5a or halogen, and wherein the 5- to 6-membered monocyclic heteroaryl is optionally substituted by C 1-3 Alkyl substituted; and R 6 C 1-3 alkyl; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment or any alternative embodiment described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, wherein R 5 Each occurrence is independently halo, -OR 5a , C 1-6 alkyl, a 4- to 7-membered monocyclic heterocyclic group or a phenyl group, and wherein said C 1-6 Each alkyl group is optionally substituted with -OR 5a Replace; and R 6 C 1-3and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment. In another alternative embodiment, R 5 Each occurrence is independently -F, -Cl, -CH3, -CH2CH3, -CF3, -OCHF2, -OCH3, -CH2OCH3, tetrahydropyranyl, phenyl, pyridyl; and R 6 is –CH3, optionally wherein R 5 It is expressed by the following formula: And the remainder of the variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment or any alternative embodiments described therein.
[0071] In an eleventh embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4 substituted 4 to 9 membered heterocyclyl; and the remainder of the variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment or any alternative embodiment described therein.
[0072] In a twelfth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4- to 6-membered monocyclic saturated heterocyclic group or an 8- to 9-membered bicyclic heterocyclic group, each of which is optionally substituted by one to three R 4 and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment or any alternative embodiments described therein.
[0073] In a thirteenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
[0074]
[0075] Each of which is optionally replaced by one to three R 4and the remaining variables are as described in the twelfth embodiment or any of the alternative embodiments described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
[0076] Each of which is optionally replaced by one to three R 4 and the remainder of the variables are as described in the twelfth embodiment or any alternative embodiment described therein.
[0077] In a fourteenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
[0078]
[0079] and the remaining variables are as described in the thirteenth embodiment or any of the alternative embodiments described therein. In one alternative, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
[0080] and the remaining variables are as described in the thirteenth embodiment or any of the alternative embodiments described therein.
[0081] In a fifteenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 Het, -C 1-3 Alkyl-Het, -C 1-3 Alkyl-C 3-6 Cycloalkyl, C 3-6 Cycloalkyl or C 1-6 Alkyl, wherein the C 3-6 Cycloalkyl and the C 1-6 The alkyl groups are each optionally substituted by one or two R 4 Replacement; R 2 H or C 1-3Alkyl; Het is a 4- to 6-membered monocyclic saturated heterocyclic group or a 6- to 7-membered bicyclic saturated heterocyclic group, wherein the 4- to 6-membered monocyclic saturated heterocyclic group and the 6- to 7-membered bicyclic saturated heterocyclic group contain one oxygen ring atom and are each optionally substituted by one or two R 4 Replace; and R 4 Each occurrence is independently –OR 4a , halogen or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally replaced by -OR 4a Replacement; R 4a H or C 1-3 and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment or any alternative embodiment described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 Het, -C 1-3 Alkyl-Het, C 3-6 Cycloalkyl or C 1-6 Alkyl, wherein the C 3-6 Cycloalkyl and the C 1-6 The alkyl groups are each optionally substituted by one or two R 4 Het is a 4- to 6-membered monocyclic saturated heterocyclic group or a 6- to 7-membered bicyclic saturated heterocyclic group, wherein the 4- to 6-membered monocyclic saturated heterocyclic group and the 6- to 7-membered bicyclic saturated heterocyclic group contain one oxygen ring atom and are each optionally substituted by one or two R 4 Replacement; R 4 Each occurrence is independently -OH, halo or C 1-3 Alkyl; R 2 H or C 1-3 alkyl; and the remainder of the variables are as described in the first aspect, or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment, or any alternative embodiment described therein.
[0082] In a sixteenth embodiment, for compounds of Formula (I), (II), (IIA) or (IIB), or pharmaceutically acceptable salts thereof, Het is oxetanyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 2-oxaspiro[3.3]heptyl or 5-oxabicyclo[2.1.1]hexyl, each of which is optionally replaced by one R 4and the remaining variables are as described in the fifteenth embodiment or any alternative embodiment described therein. In an alternative embodiment, for compounds of Formula (I), (II), (IIA) or (IIB) or pharmaceutically acceptable salts thereof, Het is oxetanyl, tetrahydro-2H-pyranyl or 5-oxabicyclo[2.1.1]hexyl, each of which is optionally replaced by one R 4 and the remainder of the variables are as described in the fifteenth embodiment or any alternative embodiment described therein.
[0083] In a seventeenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 It is expressed by the following formula:
[0084] Each of which is optionally replaced by one or two R 4 and the remaining variables are as described in the fifteenth embodiment or any alternative embodiment described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 It is expressed by the following formula:
[0085] Each of which is optionally replaced by one or two R 4 and the remainder of the variables are as described in the fifteenth embodiment or any alternative embodiment described therein.
[0086] In an eighteenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 It is expressed by the following formula:
[0087]
[0088] and the remaining variables are as described in the fifteenth embodiment or any of the alternative embodiments described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 1 It is expressed by the following formula:
[0089]
[0090] and the remainder of the variables are as described in the fifteenth embodiment or any alternative embodiment described therein.
[0091] In a nineteenth embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 2 is H or -CH3; and the remaining variables are as described in the fifteenth, sixteenth, seventeenth or eighteenth embodiment or any of the alternative embodiments described therein. In an alternative embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, R 2 is H; and the remaining variables are as described in the fifteenth, sixteenth, seventeenth or eighteenth embodiment, or any alternative embodiment described therein.
[0092] In one embodiment, for a compound of Formula (I), (II), (IIA) or (IIB) or a pharmaceutically acceptable salt thereof, each R 4 Each occurrence is independently -F, -CH3, -CH2CH2OCH3, -CH2OH, -OH or -OCH3; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, fifteenth, sixteenth, seventeenth, eighteenth or nineteenth embodiment, or any alternative embodiment described therein.
[0093] In a twentieth embodiment, the compounds of the present disclosure are of formula (III) or (IV):
[0094]
[0095] or a pharmaceutically acceptable salt thereof, wherein:
[0096] R 1 C 3-6 Cycloalkyl, Het or -CH2-Het, wherein the C 3-6 The cycloalkyl group is optionally substituted with one R 4 replace;
[0097] Het is a 4- to 6-membered monocyclic saturated heterocyclic group or a 6- to 7-membered bicyclic saturated heterocyclic group, wherein the 4- to 6-membered monocyclic saturated heterocyclic group and the 6- to 7-membered bicyclic saturated heterocyclic group both contain one oxygen ring atom and are each optionally substituted by one R 4 replace;
[0098] Ring A is a 4- to 6-membered monocyclic saturated heterocyclic group or an 8- or 9-membered bicyclic heterocyclic group, each of which is optionally substituted by one or two R 4 replace;
[0099] R 3 is phenyl, pyridyl or 5-membered heteroaryl, each of which is optionally substituted by one or two R 5 replace;
[0100] R 4 Each occurrence is independently selected from -OH, halo and C 1-3 alkyl;
[0101] R 5 Each occurrence is independently selected from halo, -OR 5a , C 1-6 alkyl, a 4- to 6-membered monocyclic heterocyclic group or a phenyl group, wherein the C 1-6 The alkyl group is optionally substituted with one to three halo or -OR 5a replace;
[0102] or two R 5 Together with its intervening atoms, it forms optionally one to three independently selected C 1-6 Alkyl, oxo and halogen R 6 a substituted 6-membered heterocyclic ring; and
[0103] R 5a H, C 1-3 Alkyl or C 1-3 haloalkyl; and the remainder of the variables are as described in the first aspect or first or second embodiment.
[0104] In a twenty-first embodiment, for compounds of formula (III) or (IV) or pharmaceutically acceptable salts thereof, Het is oxetanyl, tetrahydro-2H-pyranyl or 5-oxabicyclo[2.1.1]hexyl, each of which is optionally substituted by one R 4 replace;
[0105] Ring A is Each of which is optionally replaced by one to two R 4 replace;
[0106] R 3 for Each of which is optionally replaced by one or two R 5 replace;
[0107] or R 3 for Each of which is optionally replaced by one or two R 6 and the remaining variables are as described in the twentieth embodiment.
[0108] In a twenty-second embodiment, for a compound of formula (III) or (IV) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0109]
[0110]
[0111] And the remaining variables are as described in the twenty-first embodiment.
[0112] In a twenty-third embodiment, for the compound of formula (III) or (IV) or a pharmaceutically acceptable salt thereof, Het is represented by the following formula:
[0113]
[0114] And the remaining variables are as described in the twentieth, twenty-first or twenty-second embodiment.
[0115] In a twenty-fourth embodiment, for a compound of Formula (III) or (IV) or a pharmaceutically acceptable salt thereof, R 4 Each occurrence is independently -CH3, -OH or F; and the remainder of the variables are as described in the twentieth, twenty-first, twenty-second or twenty-third embodiment.
[0116] In a twenty-fifth embodiment, for a compound of Formula (III) or (IV) or a pharmaceutically acceptable salt thereof, R 5 Each occurrence is independently -OCF3, -OCHF2, Cl, -CH2OCH3, -CH3, -CF3, -OCH3, -CH2CH3, and the remaining variables are as described in the twentieth, twenty-first, twenty-second, twenty-third or twenty-fourth embodiment.
[0117] In a twenty-sixth embodiment, the compounds of the present disclosure are of Formula V:
[0118]
[0119] or a pharmaceutically acceptable salt thereof; wherein the variables in formula (V) are as defined above in the first aspect or the first embodiment.
[0120] In a twenty-seventh embodiment, the compounds of the present disclosure are of formula (VA) or (VB):
[0121]
[0122] or a pharmaceutically acceptable salt thereof, wherein the variables in Formulas (VA) and (VB) are as defined above in the twenty-sixth embodiment.
[0123] In a twenty-eighth embodiment, for a compound of Formula (V), (VA) or (VB) or a pharmaceutically acceptable salt thereof, R 3 is selected from the group consisting of phenyl, pyrazolyl, isoxazolyl and pyridinyl, each of which is optionally substituted by one to three R 5and the remaining variables are as described in the twenty-sixth or twenty-seventh embodiment.
[0124] In a twenty-ninth embodiment, for a compound of Formula (V), (VA) or (VB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0125] Wherein each of the above formulas is optionally replaced by one to three R 5 and the remaining variables are as described in the twenty-sixth, twenty-seventh or twenty-eighth embodiment.
[0126] In a thirtieth embodiment, for a compound of Formula (V), (VA) or (VB) or a pharmaceutically acceptable salt thereof, R 3 It is expressed by the following formula:
[0127] and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth or twenty-ninth embodiment.
[0128] In a thirty-first embodiment, for a compound of Formula (V), (VA) or (VB) or a pharmaceutically acceptable salt thereof, R 5 Each occurrence is independently halo, -OR 5a or C 1-6 alkyl; and the remainder of the variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth or thirtieth embodiment.
[0129] In a thirty-second embodiment, for a compound of Formula (V), (VA) or (VB) or a pharmaceutically acceptable salt thereof, R 7 is H or OH; and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth or thirty-first embodiment.
[0130] In a thirty-third embodiment, for a compound of Formula (V), (VA) or (VB) or a pharmaceutically acceptable salt thereof, R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula: and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first or thirty-second embodiment.
[0131] In a thirty-fourth embodiment, the compounds of the present disclosure are of formula (VI) or (VII):
[0132]
[0133] or a pharmaceutically acceptable salt thereof, wherein:
[0134] R 1 C 1-6 Alkyl, C 3-6 Cycloalkyl, Het, -CH2-C 3-4 Cycloalkyl or -CH2-Het, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl and –CH2-C 3-4 The cycloalkyl groups are each optionally substituted by one or two R 4 replace;
[0135] Het is a 4- to 6-membered monocyclic saturated heterocyclic group containing one oxygen ring atom;
[0136] Ring A is a 4- to 6-membered monocyclic saturated heterocyclic group or an 8- or 9-membered bicyclic saturated heterocyclic group, each of which is optionally substituted by one or two R 4 replace;
[0137] R 4 Each occurrence is independently selected from –OR 4a 、-CH2-OR 4a and C 1-3 alkyl;
[0138] R 4a H or C 1-3 alkyl;
[0139] R 5 For-OR 5a ;
[0140] R 5a C 1-3 wherein the remaining variables in formulas (VI) and (VII) are as defined in the third embodiment.
[0141] In a thirty-fifth embodiment, for compounds of Formula (VI) and (VII), or pharmaceutically acceptable salts thereof, Het is tetrahydropyranyl or oxetanyl; and the remaining variables are as defined in the thirty-fourth embodiment.
[0142] In a thirty-sixth embodiment, for a compound of Formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, R 1 for:
[0143] (i) optionally with one or two R 4 Substituted C 1-6 alkyl;
[0144] (ii) is represented by the following formula: or
[0145] (iii) is represented by the following formula: Each of which is optionally replaced by one or two R 4 and the remaining variables are as defined in the thirty-fourth or thirty-fifth embodiment.
[0146] In a thirty-seventh embodiment, for a compound of Formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, R 1 is –CH(CH3)CH2CH2OCH3 or CH2C(CH3)2OH, or R 1 It is expressed by the following formula: And the remaining variables are as defined in the thirty-sixth embodiment.
[0147] In a thirty-eighth embodiment, for a compound of Formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, Ring A is Each of which is optionally replaced by one to two R 4 substituted; and the remaining variables are as defined in the thirty-fourth embodiment.
[0148] In the thirty-ninth embodiment, for the compound of Formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, Ring A is And the remaining variables are as defined in the thirty-eighth embodiment.
[0149] In the fortieth embodiment, for the compound of Formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, each R 4 is independently -OH, -OCH3, -CH2OH or -CH3; and the remainder of the variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, thirty-eighth or thirty-ninth embodiment.
[0150] In a forty-first embodiment, for a compound of Formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, R 5 is -OCHF2; and the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth or fortieth embodiment.
[0151] In a forty-second embodiment, the disclosure provides a compound described herein (eg, a compound of any one of Examples 1 to 77), or a pharmaceutically acceptable salt thereof.
[0152] In a forty-third embodiment, the present disclosure provides a compound selected from the group consisting of:
[0153] 3-Methyl-4-(((1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-1,2,5-oxadiazole;
[0154] 5-(((1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2-(tetrahydro-2H-pyran-4-yl)oxazole;
[0155] (1R,3s,5S)-8-((2-methoxy-6-methylpyridin-3-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0156] (1R,3s,5S)-8-((4-chloro-1-(methoxymethyl)-1H-pyrazol-5-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0157] 3,3-Dimethyl-6-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-3,4-dihydroquinolin-2(1H)-one;
[0158] 5-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2-(tetrahydro-2H-pyran-4-yl)oxazole;
[0159] (1R,3s,5S)-8-(isochroman-7-ylsulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0160] (1R,3s,5S)-8-((5-(methoxymethyl)furan-2-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0161] 2-methyl-3-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2,4,6,7-tetrahydropyrano[4,3-c]pyrazole;
[0162] (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-((3-phenyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]octane;
[0163] 5-methyl-2-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine;
[0164] (1R,3s,5S)-8-((1,4-dimethyl-1H-pyrazol-5-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0165] (1R,3s,5S)-8-((1-ethyl-1H-pyrazol-5-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0166] 2-((8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)cyclobutan-1-ol;
[0167] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0168] 9-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-3,3-difluoro-9-azabicyclo[3.3.1]nonane;
[0169] 4-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol;
[0170] 4-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol;
[0171] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0172] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0173] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0174] 6-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.3]heptane;
[0175] 6-((1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.3]heptane;
[0176] (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0177] (1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0178] (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0179] (1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0180] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0181] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0182] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0183] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0184] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0185] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol;
[0186] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol;
[0187] 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)-2,6-difluorophenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine;
[0188] 4-(((1R,3s,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine;
[0189] 4-(((1R,3r,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine;
[0190] 4-(((1R,3s,5S)-8-((3,5-dimethylisoxazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine;
[0191] 4-(((1R,3s,5S)-8-((4,6-dimethylpyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine;
[0192] (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-((1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]octane;
[0193] (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-((1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]octane;
[0194] 4-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2-(trifluoromethyl)thiazole;
[0195] (1R,3s,5S)-8-((2,6-difluoro-4-methoxyphenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0196] (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-((1-phenyl-1H-1,2,3-triazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]octane;
[0197] 1,3-Dimethyl-5-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-1H-pyrazolo[3,4-b]pyridine;
[0198] (1R,3s,5S)-8-((3,5-dimethylpyridin-2-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0199] (1R,3s,5S)-8-((2,6-dimethylpyridin-3-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0200] 1-((8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)propan-2-ol;
[0201] 1-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-3-methylpyrrolidin-3-ol;
[0202] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(3-methoxypyrrolidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0203] 6-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.4]octane;
[0204] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(4-methoxybutan-2-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0205] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8,8'-diaza-3,8'-bis(bicyclo[3.2.1]octane);
[0206] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(3-(2-methoxyethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane;
[0207] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(3-methoxybutan-2-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0208] rac-((1R,2S)-2-(((8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclopropyl)methanol;
[0209] 3-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-3-azabicyclo[3.1.1]heptane;
[0210] 8'-((4-(difluoromethoxy)phenyl)sulfonyl)-3,8'-diaza-3,3'-bis(bicyclo[3.2.1]octane);
[0211] rac-4-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol;
[0212] rac-4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol;
[0213] (1R,3r)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol;
[0214] (1R,3r)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol;
[0215] (1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol;
[0216] (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol;
[0217] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0218] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0219] 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine;
[0220] (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0221] (1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0222] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((R)-tetrahydrofuran-3-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0223] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-fluorooxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0224] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine;
[0225] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0226] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0227] (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine;
[0228] 1-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-2-methylpropan-2-ol; and
[0229] 1-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-2-methylpropan-2-ol;
[0230] or a pharmaceutically acceptable salt thereof.
[0231] In the forty-fourth embodiment, the present disclosure provides a pharmaceutical composition comprising a compound according to any one of the preceding embodiments or a pharmaceutically acceptable salt thereof.
[0232] In the forty-fifth embodiment, the present disclosure provides a method of treating a disease or condition mediated by EBP, the method comprising administering to a subject an effective amount of a compound according to any one of embodiments one to forty-four or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in the forty-fourth embodiment.
[0233] In a forty-sixth embodiment, the present disclosure provides a compound according to any one of embodiments one to forty-four for use in treating a disease or condition mediated by EBP.
[0234] In a forty-seventh embodiment, the present disclosure provides the use of a compound according to any one of embodiments one to forty-four in the manufacture of a medicament for treating a disease or condition mediated by EBP.
[0235] Compounds and intermediates described herein can be separated and used as compounds themselves. Alternatively, when there is a part capable of forming a salt, the compound or intermediate can be separated and used as its corresponding salt. As used herein, the term "salt" or "salts" refers to an acid addition salt or a base addition salt of a compound described herein. "Salt" particularly includes "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the compound described herein, and is generally not biologically or otherwise undesirable. In many cases, the compounds of the present disclosure can form acid salts and / or base salts by virtue of the presence of an amino group and / or a carboxyl group or a group similar thereto.
[0236] Pharmaceutically acceptable acid addition salts can be formed with inorganic or organic acids, such as acetate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlortheophyllonate, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate , hydroiodide / iodide, isethionate, lactate, lactobionate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthoate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, polygalacturonate, propionate, stearate, succinate, sulfate, sulfosalicylate, tartrate, toluenesulfonate, and trifluoroacetate.
[0237] Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
[0238] Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
[0239] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
[0240] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals of columns I to XII of the periodic table. In certain embodiments, salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.
[0241] Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.
[0242] The salt can be synthesized by a compound containing an alkaline or acidic part by conventional chemical methods. Generally speaking, such salts can be prepared by reacting the free acid form of these compounds with a stoichiometric amount of a suitable base (such as a hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg or K), or by reacting the free base form of these compounds with a stoichiometric amount of a suitable acid. Such reactions are usually carried out in water or an organic solvent or a mixture of the two. Generally speaking, where feasible, it is desirable to use a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile. Additional lists of suitable salts can be found in, for example, "Remington's Pharmaceutical Sciences", 20th edition, Mack Publishing Company, Easton, Pa., (1985); and Stahl and Wermuth's "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, Weinheim, Germany, 2002).
[0243] Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described in the accompanying examples and preparations using an appropriate isotopically labeled reagent in place of the unlabeled reagent previously employed. In one embodiment, the present disclosure provides a deuterated compound as described herein or a pharmaceutically acceptable salt thereof.
[0244] Pharmaceutically acceptable solvates according to the invention include those wherein the solvent of crystallization may be isotopically substituted, for example D2O, d6-acetone, d6-DMSO.
[0245] Those skilled in the art will recognize that the compounds of the present invention may contain chiral centers and may therefore exist in different stereoisomeric forms. As used herein, the term "optical isomer" or "stereoisomer" refers to any of the various stereoisomeric configurations that may exist for a given compound of the present disclosure. It should be understood that substituents may be attached to the chiral centers of carbon atoms. Therefore, the present disclosure includes enantiomers, diastereomers, or racemates of the compounds.
[0246] "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. Where appropriate, the term "racemic" or "rac" is used to specify a racemic mixture. When specifying the stereochemistry of the compounds of the present invention, a single stereoisomer with relative and absolute configurations of two known chiral centers is specified using the conventional RS system (e.g., (1S, 2S)). "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-PrelogR-S system. When a compound is a pure enantiomer, the stereochemistry of each chiral carbon can be specified by R or S. Resolved compounds with unknown absolute configuration can be specified as (+) or (-) according to the direction in which they rotate plane polarized light (right- or left-handed) at the wavelength of the sodium D line. Alternatively, the resolved compounds can be defined via chiral HPLC by the respective retention times of the corresponding enantiomers / diastereomers.
[0247] Certain of the compounds described herein contain one or more asymmetric centers or axes of asymmetry and may therefore give rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
[0248] Unless otherwise indicated, the compounds of the present disclosure are intended to include all such possible stereoisomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)-stereoisomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g., separation on a chiral SFC or HPLC column (such as CHIRALPAK available from DAICEL Corp.) RTM and CHIRALCEL RTM ) using an appropriate solvent or solvent mixture for separation to achieve good separation). If the compound contains a double bond, the substituents may be in E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituents may have a cis or trans configuration. All tautomeric forms are also intended to be included.
[0249] How to use
[0250] The compounds disclosed herein have EBP inhibitory activity. As used herein, "EBP inhibitory activity" refers to the ability of a compound or composition to induce a detectable decrease in EBP activity in vivo or in vitro (e.g., at least a 10% decrease in EBP activity as measured by a given assay, such as a bioassay described in the Examples and known in the art).
[0251] In certain embodiments, the present disclosure provides a method of treating a disease or condition responsive to inhibition of EBP activity (referred to herein as "EBP-mediated disease or condition" or "disease or condition mediated by EBP") in a subject in need of treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0252] In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound of any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating an EBP-mediated disorder or disease in a subject in need of treatment.
[0253] In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound as described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound described herein or a pharmaceutically acceptable salt thereof, for use in treating an EBP-mediated disorder or disease in a subject in need of treatment.
[0254] In certain embodiments, the EBP-mediated disorder is colorectal cancer.
[0255] In certain embodiments, the present disclosure provides a method for treating an autoimmune disease in a subject in need of treatment. The method comprises administering to the subject a compound as described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0256] In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating an autoimmune disease in a subject in need of treatment.
[0257] In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease in a subject in need of treatment.
[0258] In certain embodiments, the autoimmune disease is multiple sclerosis (MS). The disclosed compounds can be used to treat all stages of MS, including relapsing multiple sclerosis (or relapsing forms of multiple sclerosis), relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis and clinically isolated syndrome (hereinafter referred to as "CIS").
[0259] Relapsing forms of MS (or relapsing forms of MS) include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
[0260] Relapsing-remitting MS is a phase of MS characterized by unpredictable relapses followed by periods of relative calm (remission) with no new signs of disease activity for months to years. Deficits experienced during an attack may resolve, or they may remain, the latter occurring in about 40% of attacks and becoming more common the longer a person has the disease. This describes the initial course of 80% of individuals with MS.
[0261] About 65% of people who initially have relapsing-remitting MS develop secondary progressive MS, in which they eventually experience progressive neurological decline between acute attacks without clear periods of remission. Occasionally, there may be relapses and minor remissions. The most common interval between disease onset and conversion from relapsing-remitting MS to secondary progressive MS is 19 years.
[0262] Primary progressive MS is characterized by the same symptoms as secondary progressive MS, namely, progressive neurological decline between acute attacks, without any clear remission periods and without a preceding relapsing-remitting phase.
[0263] CIS is the first attack of neurological symptoms caused by central nervous system inflammation and demyelination. By definition, this attack, which must last for at least 24 hours, is a feature of multiple sclerosis, but has not yet reached the diagnostic criteria for MS, because people who experience CIS may or may not go on to develop MS. When CIS is accompanied by lesions on brain MRI (magnetic resonance imaging), which are similar to those in MS, the patient is likely to have another attack of neurological symptoms and be diagnosed with relapsing-remitting MS. When CIS is not accompanied by lesions similar to MS on brain MRI, the patient is much less likely to suffer from MS.
[0264] In certain embodiments, the present disclosure provides a method of promoting myelination in a subject with a myelin-related disease or condition in a subject in need of treatment. The method includes administering to the subject a compound as described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0265] In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for promoting myelination in a subject suffering from a myelin-related disease or disorder in a subject in need of treatment.
[0266] In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound as described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for use in promoting myelination in a subject having a myelin-related disease or disorder in a subject in need of treatment.
[0267] In certain embodiments, the myelin-related disease or disorder is selected from multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophies, neonatal white matter damage, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), acute disseminated encephalomyelitis (ADEM), central pontine myelinolysis (CPM), adrenoleukodystrophy, Alexander's disease, Pelizaeus-Merzbacher disease (PMD), vanishing white matter disease, Wallerian Degeneration, transverse myelitis, amyotrophic lateral sclerosis (ALS), Huntington's disease (Huntington's disease), Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post-radiation injury, neurologic complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin E deficiency, isolated vitamin E deficiency syndrome, Bassen-Kornzweig syndrome, Marchiafava-Bignami syndrome, autism, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, chronic inflammatory demyelinating polyneuropathy, Guillian-Barre syndrome, Charcot-Marie-Tooth disease, Bell's palsy, and radiation-induced demyelination. demyelination) such as neuromyelitis optica (NMO), optic neuritis, infantile leukodystrophy, neonatal white matter damage, age-related dementia, and schizophrenia.
[0268] In certain embodiments, the present disclosure provides a method of treating cancer in a subject in need of treatment. The method comprises administering to the subject a compound as described herein (e.g., a compound as described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0269] In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer in a subject in need of treatment.
[0270] In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof, for use in treating cancer in a subject in need of treatment.
[0271] In certain embodiments, the cancer is colorectal cancer.
[0272] In certain embodiments, the disclosure relates to the aforementioned methods, wherein the subject is a mammal. In certain embodiments, the subject is a primate. In certain embodiments, the subject is a human.
[0273] As used herein, "effective amount" and "therapeutically effective amount" can be used interchangeably. It means an amount that is effective to treat one or more diseases, disorders or conditions as described herein, or to reduce the severity thereof. In some embodiments, the effective dose can be between 10 μg and 500 mg.
[0274]
[00136] According to the methods of the present disclosure, the compounds and compositions may be administered using any amount and any route of administration effective for treating, or lessening the severity of, one or more of the diseases, disorders, or conditions described above.
[0275] In certain embodiments, the disclosure relates to the aforementioned methods, wherein the compound is administered parenterally. In certain embodiments, the disclosure relates to the aforementioned methods, wherein the compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, rectal, intrathecally, topically or intranasally. In certain embodiments, the disclosure relates to the aforementioned methods, wherein the compound is administered systemically.
[0276] The compounds of the present invention can be used as pharmaceutical compositions (e.g., compounds of the present invention and at least one pharmaceutically acceptable carrier). As used herein, the term "pharmaceutically acceptable carrier" includes generally recognized as safe (GRAS) solvents, dispersion media, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, preservatives, drug stabilizers, buffers (e.g., maleic acid, tartaric acid, lactic acid, citric acid, acetic acid, sodium bicarbonate, sodium phosphate, etc.), etc. and combinations thereof, as known to those skilled in the art (see, e.g., Remington's Pharmaceutical Sciences, 18th edition Mack Printing Company, 1990, pp. 1289-1329). Unless any conventional carrier is incompatible with the active ingredient, it is considered to be used for treatment or pharmaceutical compositions. For the purposes of this disclosure, solvates and hydrates are considered to be pharmaceutical compositions comprising compounds of the present invention and solvents (i.e., solvates) or water (i.e., hydrates).
[0277] The formulations can be prepared using conventional dissolution and mixing steps. For example, the raw drug substance (i.e., a compound of the invention or a stable form of the compound (e.g., a complex with a cyclodextrin derivative or other known complexing agent)) is dissolved in a suitable solvent in the presence of one or more of the above-mentioned excipients. The compounds of the invention are usually formulated into pharmaceutical dosage forms to provide an easily controlled drug dosage and to provide patients with an elegant and easy-to-handle product.
[0278] The pharmaceutical composition (or preparation) for application can be packaged in a variety of ways according to the method for administering the drug. Generally speaking, the article for distribution includes a container in which a pharmaceutical preparation in an appropriate form is placed. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), pouches, ampoules, plastic bags, metal cylinders, etc. The container may also include a tamper-proof component to prevent inadvertent contact with the contents of the package. In addition, a label describing the contents of the container is also placed on the container. The label may also include appropriate warnings.
[0279] Pharmaceutical compositions containing compounds of the present disclosure are typically formulated for use as suppositories for parenteral or oral administration or alternatively.
[0280] For example, the pharmaceutical oral composition of the present disclosure can be prepared into solid form (including but not limited to capsules, tablets, pills, granules, powders or suppositories) or liquid form (including but not limited to solutions, suspensions or emulsions). The pharmaceutical composition can be subjected to conventional pharmaceutical operations, such as sterilization, and / or can contain conventional inert diluents, lubricants or buffers and adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
[0281] Typically, the pharmaceutical composition is a tablet or gelatin capsule containing the active ingredient together with
[0282] a) diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine;
[0283] b) lubricants, for example silicon dioxide, talc, stearic acid, its magnesium or calcium salts and / or polyethylene glycol; for tablets, also
[0284] c) binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; if necessary,
[0285] d) disintegrants, for example starch, agar, alginic acid or its sodium salt or effervescent mixtures; and / or
[0286] e) absorbents, colorants, flavorings and sweeteners.
[0287] Tablets may be film coated or enteric coated according to methods known in the art.
[0288] Suitable compositions for oral administration include compounds of the present disclosure in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for making pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweeteners, flavoring agents, colorants, and preservatives, so as to provide pharmaceutically elegant and palatable preparations. Tablets may contain active ingredients mixed with nontoxic pharmaceutically acceptable excipients suitable for making tablets. These excipients are, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating agents and disintegrants such as corn starch or alginic acid; adhesives such as starch, gelatin, or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc. Tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide sustained action over a longer period of time. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be employed. Formulations for oral use may be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g. calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules in which the active ingredient is mixed with water or an oil medium (e.g. peanut oil, liquid paraffin or olive oil).
[0289] Parenteral compositions (e.g., intravenous (IV) preparations) are aqueous isotonic solutions or suspensions. Parenteral compositions may be sterilized and / or contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solution promoters, salts for regulating osmotic pressure and / or buffers. In addition, they may also contain other therapeutically valuable substances. Compositions are generally prepared according to conventional mixing, granulation or coating methods, respectively, and contain about 0.1-75% or contain about 1-50% active ingredient.
[0290] The compounds of the present disclosure or their pharmaceutical compositions for subjects (e.g., humans) are generally administered orally or parenterally at a therapeutic dose of less than or equal to about 100 mg / kg, 75 mg / kg, 50 mg / kg, 25 mg / kg, 10 mg / kg, 7.5 mg / kg, 5.0 mg / kg, 3.0 mg / kg, 1.0 mg / kg, 0.5 mg / kg, 0.05 mg / kg or 0.01 mg / kg but preferably not less than about 0.0001 mg / kg. When administered intravenously via infusion, the dosage may depend on the infusion rate of the IV preparation. Generally speaking, the therapeutically effective dose of a compound, pharmaceutical composition or its combination depends on the species, body weight, age and individual condition of the subject, the disorder or disease treated or its severity. A physician, pharmacist, clinician or veterinarian of ordinary skill can easily determine the effective amount of each active ingredient necessary for preventing, treating or inhibiting the progression of a disorder or disease.
[0291] The above-mentioned dosage characteristics can be demonstrated in vitro and in vivo tests, advantageously using mammals, such as mice, rats, dogs, monkeys or their isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, such as aqueous solutions, and can also be applied in vivo enterally, parenterally, advantageously intravenously, for example as suspensions or aqueous solutions. The in vitro dosage range may be between about 10 to 3 molar concentrations and 10 to 9 molar concentrations.
[0292] definition
[0293] As used herein, "patient," "subject," or "individual" are used interchangeably and refer to a human or non-human animal. The terms include mammals, such as humans. Typically, the animal is a mammal. Subject also refers to, for example, primates (e.g., humans, male or female), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc. In certain embodiments, the animal is a primate. Preferably, the subject is a human.
[0294] As used herein, the terms "inhibit," "inhibition," or "inhibiting" refer to a reduction or suppression of a given disorder, symptom or condition or disease, or a significant decrease in the baseline activity of a biological activity or process.
[0295] As used herein, the terms "treat," "treating," or "treatment" of any disease or disorder or condition refer to the management and care of a patient for the purpose of combating a disease, disorder, or condition, and include the administration of a compound of the invention to obtain the desired pharmacological and / or physiological effect. The effect may be therapeutic, including partial or substantial achievement of one or more of the following results: partial or complete reduction in the extent of a disease, disorder, or condition; improvement or enhancement of clinical symptoms, complications, or indicators associated with a disease, disorder, or condition; or delay, inhibition, or reduction in the likelihood of progression of a disease, disorder, or condition; or elimination of a disease, disorder, or condition. In certain embodiments, the effect may be prevention of the onset of symptoms or complications of a disease, disorder, or condition.
[0296] As used herein, the term "cancer" has the generally accepted meaning in the art. The term can broadly refer to abnormal cell growth.
[0297] As used herein, the term "autoimmune disease" has the meaning generally accepted in the art. The term can broadly refer to a disease in which the host's immune system targets or attacks the host's normal or healthy tissues.
[0298] As used herein, the term "myelination" has the meaning generally accepted in the art. The term can broadly refer to the process of myelin production.
[0299] As used herein, the term "myelin-related disease or disorder", "demyelinating disorder" or "demyelinating disorder" has the meaning generally accepted in the art. These terms can broadly refer to diseases or disorders involving myelin damage.
[0300] As used herein, a subject (preferably a human) is "in need of" a treatment if the subject would benefit biologically, medically or in quality of life from such treatment.
[0301] As used herein, the phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." In general, the term "optionally substituted" means that hydrogen radicals in a given structure are replaced with the radical of a specified substituent. Specific substituents are described in the definitions and in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent at each position may be the same or different.
[0302] As used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon moiety. 1-4 "Alkyl" refers to an alkyl group having 1 to 4 carbon atoms. The term "C 1-3 Alkyl" and "C 1-2 "C 1-4 Representative examples of "alkyl" include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl. Similarly, the alkyl portion of an alkoxy group (i.e., the alkyl moiety) has the same definition as above. When indicated as "optionally substituted", the alkane group or alkyl moiety may be unsubstituted or substituted with one or more substituents (generally one to three substituents, except in the case of halogen substituents such as perchloro or perfluoroalkyl).
[0303] As used herein, the term "alkoxy" refers to a fully saturated branched or unbranched alkyl moiety attached through an oxygen bridge (ie, --O--C 1-4 Alkyl groups, where C 1-4 Alkyl is as defined herein). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, and the like. Preferably, the alkoxy group has about 1-4 carbons, more preferably about 1-2 carbons. The term "C 1-2 "Alkoxy" should be interpreted accordingly.
[0304] As used herein, the term “C 1-4 Alkoxy C 1-4 "Alkyl" means a C 1-4 An alkyl group in which at least one hydrogen atom is replaced by a C 1-4 Alkoxy substitution. C 1-4 Alkoxy C 1-4 The alkyl group is attached to the remainder of the molecule described herein through the alkyl group.
[0305] The number of carbon atoms in a group is indicated herein by the prefix "C x-xx ", where x and xx are integers. For example, "C 1-3 "Alkyl" is an alkyl group having 1 to 3 carbon atoms.
[0306] "Halogen" or "halo" may be fluorine, chlorine, bromine or iodine.
[0307] As used herein, the term "halo-substituted-C 1-4 Alkyl" or "C 1-4 "Haloalkyl" refers to a C 1-4 An alkyl group in which at least one hydrogen atom is replaced by a halogen atom. 1-4 The haloalkyl group may be a monohalogenated -C 1-4 Alkyl, dihalogenated-C1-4 Alkyl or polyhalogenated-C 1-4 Alkyl groups include perhalogenated-C 1-4 Alkyl. Monohalogenated-C 1-4 The alkyl group may have one iodo, bromo, chloro or fluoro group within the alkyl group. 1-4 Alkyl and polyhalogenated-C 1-4 The alkyl group may have two or more identical halogen atoms or a combination of different halogen groups within the alkyl group. 1-4 The alkyl group contains up to 9, or 8, or 7, or 6, or 5, or 4, or 3, or 2 halo groups. 1-4 Non-limiting examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl. 1-4 An alkyl group is a C 1-4 Alkyl group.
[0308] The term "aryl" refers to an aromatic carbocyclic monocyclic ring or two fused ring systems containing 6 to 10 carbon atoms. Examples include phenyl and naphthyl.
[0309] The term "heteroaryl" refers to a 5 to 12-membered aromatic group containing 1 to 4 heteroatoms selected from N, O and S. In some cases, the nitrogen atom in the heteroaryl can be quaternized. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring", "heteroaryl group" or "heteroaromatic". The heteroaryl group can be monocyclic or bicyclic. Monocyclic heteroaryl includes, for example, pyrazolyl, imidazolyl, oxazolyl, pyridyl, furyl, oxadiazolyl, thienyl, etc. Bicyclic heteroaryl includes a group in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings. Non-limiting examples include pyrazolopyridyl, pyrazolopyridyl, benzotriazolyl, imidazopyridyl and indolyl.
[0310] The term "carbocycle" or "carbocyclyl" refers to a 4 to 12-membered saturated or partially unsaturated hydrocarbon ring, and may exist as a monocycle, a bicyclic ring (including a condensed carbocycle, a spirocarbocycle or a bridged carbocycle) or a spirocycle. Bicyclic carbocyclyl groups include, for example, unsaturated carbocyclic groups fused to another unsaturated carbocyclic group, a cycloalkyl group or an aryl group, such as 2,3-dihydroindenyl, decahydronaphthyl and 1,2,3,4-tetrahydronaphthyl. Unless otherwise indicated, carbocycles generally contain 4 to 10 ring members.
[0311] The term "C 3-6 "Cycloalkyl" refers to a fully saturated carbocyclic ring (eg, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl).
[0312] The term "heterocycle" or "heterocyclyl" refers to a 4 to 12-membered saturated or partially unsaturated heterocycle containing 1 to 4 heteroatoms independently selected from N, O and S. The heterocyclyl group can be a monocyclic or bicyclic ring (e.g., a bridged bicyclic ring, a condensed bicyclic ring or a spiral bicyclic ring). Examples of monocyclic saturated or partially unsaturated heterocyclic groups include, but are not limited to, oxetane, tetrahydrofuranyl, tetrahydropyranyl and piperidinyl. Bicyclic heterocyclyl groups include, for example, unsaturated heterocyclic groups fused to another unsaturated heterocyclic group, cycloalkyl, aryl or heteroaryl ring, such as tetrahydro-3H-[1,2,3]triazolo[4,5-c]pyridyl, 2-oxa-6-azaspiro[3.3]heptyl, 5-oxabicyclo[2.1.1]hexyl (hexanyl) and 9-azabicyclo[3.3.1]nonyl (nonanyl). In some embodiments, the heterocyclyl group is a 4 to 6-membered monocyclic heterocyclyl group. In some embodiments, the heterocyclyl group is a 4 to 6-membered monocyclic saturated heterocyclyl group. In some embodiments, the heterocyclyl group is an 8 to 10-membered bicyclic heterocyclyl group. In some embodiments, the heterocyclyl group is an 8 to 10-membered bicyclic saturated heterocyclyl group.
[0313] As used herein, the term "spiro" ring means a bicyclic ring system in which the two rings share one common atom. Examples of spiro rings include 2-oxa-6-azaspiro[3.3]heptyl and the like.
[0314] The term "fused" ring refers to a bicyclic ring system that shares two adjacent ring atoms. A fused heterocyclic ring has a ring system in which at least one ring atom contains a heteroatom selected from O, N and S (eg, 3-oxabicyclo[3.1.0]hexane).
[0315] As used herein, the term "bridged" refers to a 5- to 10-membered ring moiety that is linked at two non-adjacent ring atoms (eg, 5-oxabicyclo[2.1.1]hexane).
[0316] The phrase "pharmaceutically acceptable" means that the substance, composition or dosage form must be compatible chemically and / or toxicologically with the other ingredients comprising the formulation and / or the mammal to be treated therewith.
[0317] Unless otherwise indicated, the term "compound of the present disclosure" refers to compounds of formula (I) and all stereoisomers (including diastereomers and enantiomers), rotamers, tautomers, isotope-labeled compounds (including deuterium substitution). When there is a part capable of forming a salt, the salt, particularly a pharmaceutically acceptable salt, is also included.
[0318] As used herein, the terms "a", "an", "said" and similar terms used in the context of the present disclosure (particularly in the context of the claims) should be interpreted as covering both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present invention and does not limit the scope of the claimed invention.
[0319] The intermediates and compounds of the present invention may also exist in different tautomeric forms, and all such forms are encompassed within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be interconverted via a low energy barrier. For example, proton tautomers (also referred to as prototropic tautomers) include interconversions via the migration of a proton, such as keto-enol and imine-enamine isomerizations. The specific example of a proton tautomer is an imidazole moiety in which a proton can migrate between two ring nitrogens. Valence tautomers include interconversions by reorganization of some of the bonding electrons.
[0320] In one embodiment, the disclosure relates to a compound of formula (I) as defined herein in free form. In another embodiment, the disclosure relates to a compound of formula (I) as defined herein in salt form. In another embodiment, the disclosure relates to a compound of formula (I) as defined herein in acid addition salt form. In another embodiment, the disclosure relates to a compound of formula (I) as defined herein in pharmaceutically acceptable salt form. In yet another embodiment, the disclosure relates to a compound of formula (I) as defined herein in pharmaceutically acceptable acid addition salt form. In yet another embodiment, the disclosure relates to any one of the compounds in the Examples in free form. In yet another embodiment, the disclosure relates to any one of the compounds in the Examples in salt form. In yet another embodiment, the disclosure relates to any one of the compounds in the Examples in acid addition salt form. In yet another embodiment, the disclosure relates to any one of the compounds in the Examples in pharmaceutically acceptable salt form. In yet another embodiment, the disclosure relates to any one of the compounds in the Examples in pharmaceutically acceptable acid addition salt form.
[0321] The disclosed compounds can be synthesized by synthetic routes including processes analogous to those well known in the chemical arts, particularly in light of the description contained herein. Starting materials are generally available from commercial sources such as Sigma-Aldrich, or are readily prepared using methods well known to those skilled in the art (e.g., by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, Vols. 1-19, Wiley, New York (1967-1999 editions) or Beilsteins Handbuch der organischen Chemie, 4, Aufl. Ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
[0322] For the purpose of illustration, the reaction scheme described below provides a potential approach for synthesizing compounds disclosed herein and key intermediates. For a more detailed description of each reaction step, see the Examples section below. Although specific starting materials and reagents are described in the scheme and discussed below, other starting materials and reagents can be easily replaced to provide multiple derivatives and / or reaction conditions.
[0323] Example
[0324] abbreviation:
[0325] PE = Petroleum Ether
[0326] EtOAc=EA=ethyl acetate
[0327] ESI = Electrospray Ionization
[0328] MeOH = methanol
[0329] EtOH = ethanol
[0330] DCE = 1,2-dichloroethane
[0331] DCM = dichloromethane
[0332] CHCl3=Chloroform
[0333] HCl = Hydrochloric acid
[0334] H2O=water
[0335] IPA = Isopropyl Alcohol
[0336] LCMS = Liquid chromatography mass spectrometry
[0337] HFIP = Hexafluoro-2-propanol
[0338] HPLC = High Pressure Liquid Chromatography
[0339] THF = Tetrahydrofuran
[0340] MeCN=ACN=acetonitrile
[0341] MgSO4 = Magnesium sulfate
[0342] DMSO = dimethyl sulfoxide
[0343] AcOH = acetic acid
[0344] TFA = trifluoroacetic acid
[0345] DIPEA = diisopropylethylamine
[0346] N2 = Nitrogen
[0347] NH4HCO3=ammonium bicarbonate
[0348] t-BuOH = tert-butyl alcohol
[0349] NH4Cl = Ammonium chloride
[0350] NaH = Sodium hydride
[0351] Na2SO4=Sodium sulfate
[0352] K2CO3=Potassium carbonate
[0353] NaHCO3 = Sodium bicarbonate
[0354] NaBH(OAc)3=STAB=sodium triacetoxyborohydride
[0355] SiO2 = Silicon dioxide
[0356] PDA = Photodiode Array Detection
[0357] General approach
[0358] LCMS instrument specifications:
[0359] Agilent Technologies 1200 Series LC / MSD Systems: DAD\ELSD Alltech 3300 and Agilent LC\MSD G6130A, G6120B mass spectrometers.
[0360] Agilent Technologies 1260 Infinity LC / MSD system: DAD\ELSD Alltech 3300 and Agilent LC\MSD G6120B mass spectrometer.
[0361] Agilent Technologies 1260Infinity II LC / MSD system: DAD\ELSD G7102A1290Infinity II and Agilent LC\MSD G6120B mass spectrometer.
[0362] Agilent 1260 Series LC / MSD System: DAD\ELSD and Agilent LC\MSD (G6120B) mass spectrometer.
[0363] UHPLC Agilent 1290 Series LC / MSD System: DAD\ELSD and Agilent LC\MSD (G6125B) mass spectrometer.
[0364] HPLC analysis method specifications:
[0365] ·Column: Agilent Poroshell 120SB-C18 4.6x 30mm 2.7μm, equipped with UHPLC GuardInfinity Lab Poroshell 120SB-C18 4.6x 5mm 2.7μm
[0366] Column temperature, 60°C
[0367] Injection volume 0.5μL
[0368] Modifier: Formic acid 0.1% (vol / vol) concentration
[0369] Method: 99% water / 1% MeCN (initial condition), hold initial condition for 0.1 min, linear gradient to 0% water / 100% MeCN at 1.5 min, hold 0% water / 100% MeCN to 1.73 min, linear gradient to 99% water / 1% MeCN at 1.74 min. Flow rate, 3.0 mL / min.
[0370] UV scan: 207-223nm, 246-262nm, 272-288nm
[0371] QC analysis LC / MS method conditions:
[0372] Ammonium Hydroxide (Alkaline pH) Conditions
[0373] MS mode: MS: ESI + scan range 165-650 Daltons
[0374] PDA: 200-400nm scanning range
[0375] Column: Waters ACQUITY UPLC BEH C18 2.1x50 mm, 1.7 μm; Part No. 186002350
[0376] Modifier: ammonium hydroxide 0.2% (vol / vol) concentration
[0377] Method: 95% water / 5% MeCN (initial condition) linear gradient to 5% water / 95% MeCN at 3.75 min, maintain 5% water / 95% MeCN to 4 min. Flow rate, 0.8 mL / min.
[0378] Trifluoroacetic acid (acidic pH) conditions
[0379] MS mode: MS: ESI + scan range 165-650 Daltons
[0380] PDA: 200-400nm scanning range
[0381] Column: Waters ACQUITY UPLC BEH C18 2.1x50 mm, 1.7 μm; Part No. 186002350
[0382] Modifier: trifluoroacetic acid 0.1% (vol / vol) concentration
[0383] Method: 95% water / 5% MeCN (initial conditions) linear gradient to 5% water / 95% MeCN at 3.75 min,
[0384] Maintain 5% water / 95% MeCN for 4 min. Flow rate, 0.8 mL / min.
[0385] General preparative HPLC conditions:
[0386] Ammonium Hydroxide (Alkaline pH) Conditions
[0387] Flow rate: 30mL / min
[0388] MS mode: MS: ESI + scan range 165-650 Daltons
[0389] PDA: 200-400nm scanning range
[0390] Column: Waters XSELECT CSH C18 PREP 19x100 mm, 5μm; Part No. 186005421
[0391] Modifier: 0.2% ammonium hydroxide (vol / vol) concentration
[0392] Method: A% water / B% MeCN (initial conditions) linear gradient to A% water / B% MeCN at 8 min, increased to 5% water / 95% MeCN at 8.5 min, maintained at 5% water / 95% MeCN to 10 min.
[0393] Flow rate: 50mL / min
[0394] MS mode: MS: ESI + scan range 165-650 Daltons
[0395] PDA: 200-400nm scanning range
[0396] Column: Waters XSELECT CSH C18 PREP 30x100 mm, 5 μm; Part No. 186005425
[0397] Modifier: 0.2% NH4OH (volume / volume) concentration
[0398] Method: A% water / B% MeCN (initial conditions) linear gradient to A% water / B% MeCN at 8 min, increased to 5% water / 95% MeCN at 8.5 min, maintained at 5% water / 95% MeCN to 10 min.
[0399] Flow rate, 60 mL / min
[0400] MS mode: MS: ESI + scan range 165-650 Daltons
[0401] PDA: 200-400nm scanning range
[0402] Column: Waters XSELECT CSH C18 PREP 30x50 mm, 5 μm; Part No. 186005423
[0403] Modifier: 0.2% NH4OH (volume / volume) concentration
[0404] Method: A% water / B% MeCN (initial conditions) linear gradient to A% water / B% MeCN at 8 min, increased to 5% water / 95% MeCN at 8.5 min, maintained at 5% water / 95% MeCN to 10 min.
[0405] Trifluoroacetic acid (acidic pH) conditions
[0406] Flow rate, 30 mL / min
[0407] MS mode: MS: ESI + scan range 165-650 Daltons
[0408] PDA: 200-400nm scanning range
[0409] Column: Waters Sunfire OBD C18 PREP 19x100 mm, 5 μm; Part No. 186002567
[0410] Modifier: 0.1% trifluoroacetic acid (volume / volume) concentration
[0411] Method: A% water / B% MeCN (initial conditions) linear gradient to A% water / B% MeCN at 8 min, increased to 5% water / 95% MeCN at 8.5 min, maintained at 5% water / 95% MeCN to 10 min.
[0412] Flow rate, 50 mL / min
[0413] MS mode: MS: ESI + scan range 165-650 Daltons
[0414] PDA: 200-400nm scanning range
[0415] Column: Waters Sunfire OBD C18 PREP 30x100 mm, 5 μm; Part No. 186002572
[0416] Modifier: 0.1% trifluoroacetic acid (volume / volume) concentration
[0417] Method: A% water / B% MeCN (initial conditions) linear gradient to A% water / B% MeCN at 8 min, increased to 5% water / 95% MeCN at 8.5 min, maintained at 5% water / 95% MeCN to 10 min.
[0418] Flow rate, 60 mL / min
[0419] MS mode: MS: ESI + scan range 165-650 Daltons
[0420] PDA: 200-400nm scanning range
[0421] Column: Waters Sunfire OBD C18 PREP 30x50 mm, 5 μm; Part No. 186002570
[0422] Modifier: 0.1% trifluoroacetic acid (volume / volume) concentration
[0423] Method: A% water / B% MeCN (initial conditions) linear gradient to A% water / B% MeCN at 8 min, increased to 5% water / 95% MeCN at 8.5 min, maintained at 5% water / 95% MeCN to 10 min.
[0424] Preparation of intermediates
[0425] Intermediate 1: (1R, 3r, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0426]
[0427] 1. Synthesis of tert-butyl (1R, 3r, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0428]
[0429] A mixture of (1R, 3r, 5S)-3-amino-8-azabicyclo [3.2.1] octane-8-carboxylic acid tert-butyl ester (15g, 66.3mmol), 1,5-dibromo-3-methylpentane (17.79g, 72.9mmol) and DIPEA (25.4mL, 145.8mmol) in IPA (250L) was heated to reflux for 72h. The solvent was removed in vacuo, and the residue was diluted with water (100mL) and extracted with EtOAc (3x50mL). The combined organic matter was dried (Na2SO4), filtered and evaporated to dryness to obtain (1R, 3r, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo [3.2.1] octane-8-carboxylic acid tert-butyl ester (19g, crude product; purity 90%) as a yellow oil, which can be used in the next step without further purification. LCMS m / z=309.2[M+H] + .
[0430] 2. Synthesis of (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0431]
[0432] TFA (14mL, 183mmol) is added to a solution of (1R, 3r, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-tert-butyl carboxylate (18.8g, 61.0mmol) in DCM (100mL) and the resulting solution is stirred at room temperature for 48h. The reaction mixture is evaporated to dryness in a vacuum, the residue is diluted with saturated NaHCO3 aqueous solution and extracted with EtOAc (3x 50mL). The combined organic matter is washed with water (50mL), brine (50mL), dried (Na2SO4), filtered and evaporated to dryness in a vacuum to obtain (1R, 3r, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (11.2g, 88%) as a yellow solid, which can be used without further purification. LCMS m / z=209.2[M+H] + .
[0433] Intermediate 2: (1R, 3s, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0434]
[0435] 1. Synthesis of tert-butyl (1R, 3s, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0436]
[0437] DIPEA (340 μL, 1.9 mmol) is added to (1R, 3s, 5S) -3- amino -8- azabicyclo [3.2.1] octane -8- tert-butyl formate (200 mg, 0.9 mmol) and 1,5- dibromo -3- methyl - pentane (237 mg, 1.0 mmol) in IPA (10 mL) solution, and the reaction mixture is heated to reflux for 72 h. The reaction mixture is evaporated to dryness in a vacuum. The residue is diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic matter is dried (Na2SO4), filtered and evaporated to dryness to obtain (1R, 3s, 5S) -3- (4- methylpiperidin -1- bases) -8- azabicyclo [3.2.1] octane -8- tert-butyl formate (200 mg, crude product) as a yellow oil, which can be used without further purification. LCMS m / z=309.2[M+H] + .
[0438] 2. Synthesis of (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0439]
[0440] TFA (13.8mL, 180mmol) is added to (1R, 3s, 5S) -3- (4- methylpiperidin-1-yl) -8- azabicyclo [3.2.1] octane -8- tert-butyl formate (18.5g, 60mmol) in DCM (100mL) solution and the resulting solution is stirred at room temperature for 48h. The reaction mixture is concentrated under reduced pressure, and residue is dissolved in saturated NaHCO aqueous solution and extracted with EtOAc (3x50mL). The combined organic matter is washed with water (50mL), salt solution (50mL), dried (Na SO ), filtered and evaporated to dryness in a vacuum. The resulting yellow oil was crystallized from DCM / hexanes (100 / 300 mL), the solid was collected by cold filtration and air-dried to give (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (6.3 g, 50%) as a yellow solid. LCMS m / z=209.2 [M+H] + .
[0441] Intermediate 3: (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-amine
[0442]
[0443] 1. Synthesis of tert-butyl ((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)carbamate
[0444]
[0445] 4-(difluoromethoxy)benzenesulfonyl chloride (1.21g, 5mmol) is added to a solution of ((1R, 3r, 5S)-8-azabicyclo [3.2.1] oct-3-yl) tert-butyl carbamate (1.13g, 5.0mmol) and DIPEA (1.74mL, 10.0mmol) in DCM (25mL), and the mixture is stirred at room temperature overnight. The organic phase is washed with saturated NaHCO3 aqueous solution and water, dried (MgSO4), filtered and evaporated to dryness in a vacuum. The residue is purified by column chromatography (24gSiO2, 10-40% EtOAc in heptane) to obtain tert-butyl ((1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)-sulfonyl)-8-azabicyclo [3.2.1] oct-3-yl) carbamate (1.42g, 66%) as a white solid. LCMS m / z=433.1[M+H]+
[0446] 2. Synthesis of (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-amine
[0447]
[0448] TFA (200 μL, 2.71 mmol) was added dropwise to a solution of tert-butyl ((1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate (468 mg, 1.1 mmol) in HFIP (3 mL) at room temperature, and the resulting mixture was stirred overnight at room temperature. The reaction mixture was evaporated to dryness in vacuo, and the resulting residue was co-evaporated with MeCN (x3) to give (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (543 mg, 100%) as a white solid. LCMS m / z=333.1 [M+H] + .
[0449] Intermediate 4: (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine
[0450]
[0451] 1. Synthesis of tert-butyl ((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)carbamate
[0452]
[0453] 4-(Difluoromethoxy)benzenesulfonyl chloride (1.21 g, 5 mmol) was added to a solution of tert-butyl ((1R, 3s, 5S)-8-azabicyclo[3.2.1]octan-3-yl)carbamate (1.13 g, 5.0 mmol) and DIPEA (1.74 mL, 10.0 mmol) in DCM (25 mL) and stirred overnight at room temperature. The mixture was diluted with EtOAc, washed with aqueous NaHCO3 and water, dried (MgSO4), filtered and evaporated to dryness in vacuo. The resulting residue was triturated with MeCN to give tert-butyl ((1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)-sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate (1.88 g, 87%) as a white solid. LCMS m / z=433.1[M+H] + .
[0454] 2. Synthesis of (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-amine
[0455]
[0456] TFA (220 μL, 2.9 mmol) was added dropwise to a solution of tert-butyl ((1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate (468 mg, 1.1 mmol) in HFIP (3 mL) at room temperature, and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was evaporated to dryness in vacuo and the resulting residue was co-evaporated with MeCN (x3) to give (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine trifluoroacetate (521 mg, 100%) as a white solid. LCMS m / z=333.1[M+H] + .
[0457] Intermediate 5: 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one
[0458]
[0459] DIPEA (2.15 mL, 12.4 mmol) was added to a mixture of (1S, 5R)-8-azabicyclo [3.2.1] octan-3-one hydrochloride (666 mg, 4.1 mmol) and 4- (difluoromethoxy) benzenesulfonyl chloride (656 μL, 4.1 mmol) in DCM (8 mL). The reaction mixture was stirred at room temperature for 6 h. The organic phase was washed with saturated NaHCO3 aqueous solution, water, dried (MgSO4), filtered and evaporated to dryness. The resulting residue was purified by column chromatography (80 g SiO2, 10-40% EtOAc in heptane) to give 8- ((4- (difluoromethoxy) phenyl) sulfonyl) -8-azabicyclo [3.2.1] octan-3-one (1.85 g, 79%) as a white solid. LCMS m / z = 332.0 [M + H] + .
[0460] Intermediate 6. 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one
[0461]
[0462] DIPEA (92 μL, 0.5 mmol) was added dropwise to a solution of 8-azabicyclo[3.2.1]octan-3-one hydrochloride (177 mg, 1.1 mmol) and 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride (263 mg, 1.0 mmol) in DCM (5 mL), and the resulting mixture was stirred at room temperature overnight.
[0463] The reaction mixture was diluted with EtOAc, the organic phase was washed with saturated aqueous NaHCO3 and water, dried (MgSO4), filtered and evaporated to dryness in vacuo. The residue was purified by column chromatography (24 g SiO2, 20-50% EtOAc in heptane) to give 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (322 mg, 91%) as a colorless oil. LCMS m / z=349.1[M+H] + .
[0464] Intermediate 7. 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0465]
[0466] 1. Synthesis of tert-butyl (1R, 3s, 5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0467]
[0468] NaBH(OAc)3(36.54g, 172mmol) was added to a solution of (1R, 3s, 5S)-3-formyl-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (27.5g, 115mmol) and morpholine (10.52g, 121mmol) in DCE (300mL) in batches at room temperature, and the resulting mixture was stirred overnight at room temperature. MeOH (150mL) was added, and the reaction mixture was evaporated to dryness. The residue was quenched with 15% potassium carbonate solution and extracted with EtOAc (2x 250mL). The combined organics were washed with water, dried (Na2SO4), filtered and evaporated in vacuo to obtain (1R, 3s, 5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (27.4g, 77%).
[0469] 2. Synthesis of 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0470]
[0471] (1R, 3s, 5S) -3- (morpholinylmethyl) -8- azabicyclo [3.2.1] octane -8- tert-butyl carboxylate (27.4 g, 88.3 mmol) was dissolved in a MeOH solution of HCl (150 mL) and stirred overnight. The solvent was evaporated and THF (150 mL) was added to the residue. The precipitate was collected by filtration, washed with THF (2 x 75 mL) and dried to give 4- (((1R, 3s, 5S) -8- azabicyclo [3.2.1] octane -3- yl) methyl) morpholine dihydrochloride (17.6 g, 70%) as a white solid. 1 H NMR (500MHz, DMSO-d6) δ (ppm): 3.89 (dd, J=14.4, 10.3Hz, 6H), 3.45 (d, J=12.6Hz, 2H), 2.99 (q, J=12.6, 11 .8Hz,2H),2.91(t,J=6.0Hz,2H),2.33(dt,J=11.8,6.2Hz,1H),1.96–1.83(m,6H),1.63(t,J=12.6Hz,2H).
[0472] Intermediate 8: 4-(((1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0473]
[0474] 4-(((1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine was prepared from tert-butyl (1R,3r,5S)-3-formyl-8-azabicyclo[3.2.1]octane-8-carboxylate and morpholine using a similar 2-step procedure as described for Intermediate 7. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 4.02–3.82 (m, 6H), 3.47 (d, J = 12.4Hz, 2H), 3.08– 2.85(m,4H),2.36(dd,J=11.4,5.9Hz,1H),2.00–1.82(m,6H),1.71–1.58(m,2H). LCMS m / z=211.2[M+H] + .
[0475] Intermediate 9: (1R, 3s, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine
[0476]
[0477] 1. Synthesis of tert-butyl (1R,3s,5S)-3-(2,2,2-trifluoroacetamido)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0478]
[0479] (1R, 3s, 5S) -3- amino -8- azabicyclo [3.2.1] octane -8- tert-butyl formate (2.5g, 11mol) was dissolved in anhydrous DCM (50mL), and trimethylamine (1.11g, 11mmol) was added. The mixture was cooled to 0 ° C and trifluoroacetic anhydride (2.31g, 11mmol) was added dropwise. The reaction mixture was warmed to 20 ° C and stirred for 18h. The resulting mixture was washed with water (100mL) and NaHSO4 aqueous solution (50mL), dried over Na2SO4, filtered and concentrated in vacuo to obtain (1R, 3s, 5S) -3- (2,2,2- trifluoroacetamido) -8- azabicyclo [3.2.1] octane -8- tert-butyl formate (3.38g, 95% yield) as a yellow oil.
[0480] 2. Synthesis of N-((1R,3s,5S)-8-azabicyclo[3.2.1]oct-3-yl)-2,2,2-trifluoroacetamide
[0481]
[0482] Tert-butyl (1R, 3s, 5S)-3-(2,2,2-trifluoroacetamido)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.38 g, 10.5 mmol) was dissolved in 4N HCl / dioxane solution, and the reaction mixture was stirred for 4 h at 20° C. The volatiles were removed in vacuo, and the residue was washed with ether (50 mL) and dried in vacuo to obtain N-((1R, 3s, 5S)-8-azabicyclo[3.2.1]octan-3-yl)-2,2,2-trifluoroacetamide (2.64 g, 97% yield) as a white solid.
[0483] 3. Synthesis of 2,2,2-trifluoro-N-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide
[0484]
[0485] N-((1R, 3s, 5S)-8-azabicyclo[3.2.1]octan-3-yl)-2,2,2-trifluoroacetamide (1 g, 4.5 mmol) was suspended in anhydrous DCM (50 mL), and the mixture was cooled to 0°C before 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride (1 g, 3.9 mmol) was added in one portion, followed by slow addition of DIPEA (1 g, 7.8 mmol). The reaction mixture was warmed to 20°C and stirred at 20°C for 18 h. The resulting mixture was washed with water (100 mL) and NaHCO3 aqueous solution (100 mL), dried over Na2SO4 and filtered through silica gel (100 mL) washed with MTBE (100 mL). The volatiles were removed in vacuo to afford 2,2,2-trifluoro-N-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide (1.7 g, 97% yield) as a viscous yellow oil.
[0486] 4. Synthesis of (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine
[0487]
[0488] 2,2,2-trifluoro-N-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide (1.7 g, 3.8 mmol) was dissolved in methanol (50 mL) and a solution of NaOH (0.76 g, 19 mmol) in water (10 mL) was added. The resulting mixture was stirred at 20 ° C for 72 h. The volatiles were removed in vacuo, and the residue was diluted with NaHSO4 aqueous solution (250 mL) and washed with MTBE (100 mL). The acidic layer was basified with NaOH and extracted with MTBE (3×100 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to afford (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (1.3 g, 3.7 mmol, 98% yield) as a yellow oil. 1 H NMR (500 MHz, CHLOROFORM-d) δ 8.44 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.1 Hz, 1H), 4.28–4.14 (m, 2H), 3.11 (tt, J = 11.6, 5.9 Hz, 1H), 2.94 (d, J = 1.7 Hz, 3H), 2.15–1.98 (m, 2H), 1.90 (ddd, J = 13.5, 5.5, 2.8 Hz, 2H), 1.81–1.70 (m, 2H), 1.57–1.30 (m, 4H).
[0489] Examples 1, 2 and 40
[0490] The title compound was prepared using the single-step library protocol as described below. Each reaction was performed on a scale of approximately 50 mg of target product.
[0491]
[0492] The appropriate sulfonyl chloride (RS02Cl, 1.1 eq) was added to a solution of (1R, 3r, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (Intermediate 1, 1.0 eq) and DIPEA (2.5 eq) in anhydrous MeCN (1.2 mL), and the resulting mixture was stirred at room temperature for 16 h. The solvent was evaporated in vacuo, and the residue was dissolved in DMSO (800 μL) and purified by preparative HPLC (YMC Actus Trial C18 20x 100mm, 5 μm; MeOH / water + 0.1% NH4OH) to give the title compound. Gradient optimization was performed for each compound.
[0493]
[0494]
[0495] Examples 3-13 and 41-47
[0496] General Step B
[0497] The title compound was prepared using a single-step library protocol as described below at a scale of approximately 50 mg of target product.
[0498]
[0499] The appropriate sulfonyl chloride (RSOC1) (1.1 equivalents) was added to a solution of (1R, 3s, 5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (intermediate 2, 1.0 equivalents) and DIPEA (2.5 equivalents) in anhydrous MeCN (1.2 mL), and the reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated to dryness in a vacuum, the residue was dissolved in DMSO (800 μL), and the title compound was obtained by preparative HPLC purification. The solvent gradient for each compound was optimized.
[0500] Preparative HPLC-A: Waters SunFire C18 19 x 100 mm, 5 μm; water / methanol
[0501] Preparative HPLC-B: YMC Actus Trial C18 20x 100mm, 5μm; water / MeCN+0.1% NH4OH
[0502]
[0503]
[0504]
[0505]
[0506]
[0507] Examples 14-16 and 48-58
[0508] Primary amine (RNH2) and secondary amine (R 1 R 2 General procedure for reductive amination of NH
[0509]
[0510] The title compound was prepared using a single step reductive amination protocol at a scale of approximately 50 mg of target product using either the primary amine or secondary amine protocol outlined below.
[0511] Primary Amine Protocol: The appropriate primary amine (RNH2, 1.3 eq.), 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5, 1.0 eq.) and NaBH(OAc)3 (4.0 eq.) were dissolved in CHCl3 (1.2 mL) and AcOH (1.2 eq.) and the mixture was stirred at room temperature for 24 h. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in 5% ammonia in MeOH (1.2 mL) and stirred at room temperature for 0.5 h. The mixture was concentrated under reduced pressure, the residue was dissolved in DMSO (0.7 mL) and purified by preparative HPLC (YMC Actus Triart C18 20 x 100 mm, 5 μm; gradient mixture water-MeOH+0.1% NH4OH) to give the title compound. If the primary amine was used as the HCl salt, an additional 1.4 eq. was required. DIPEA per equivalent of acid was added to the reaction mixture. The molar ratio of the starting materials and the overall reaction conditions were unchanged.
[0512] Secondary amine protocol: NaBH(OAc)3 (3.0 equiv) was added to 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5, 1.0 equiv) and the appropriate secondary amine (R 1 R 2 NH, 1.1 equivalents) in a solution of 1,2-dichloroethane (1 mL), and the resulting solution was stirred at 50 ° C for 16 h. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in saturated NaHCO3 aqueous solution and extracted with EtOAc (2x10 mL). The combined organics were washed with water (10 mL), brine (10 mL), dried (Na2SO4) and evaporated to dryness in vacuo. The residue was dissolved in DMSO (500 μL) and purified by preparative HPLC (YMC Actus Triart C18 20x 100mm, 5 μm; gradient mixture water-MeOH+0.1% NH4OH) to obtain the title compound.
[0513]
[0514]
[0515]
[0516]
[0517] Example 17: 4-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol
[0518]
[0519] DIPEA (36 μL, 0.2 mmol) was added to a mixture of 1,6-dioxaspiro[2.5]octane (11 mg, 0.1 mmol) and (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3, 41 mg, 0.1 mmol) in EtOH (2 mL), and the mixture was stirred overnight at 60° C. Additional 1,6-dioxaspiro[2.5]octane was added, and heating at 60° C. was continued overnight. The reaction mixture was evaporated to dryness and dissolved in DMSO and purified by preparative HPLC (Waters Xselect CSH Prep C18 30 x 100mm, 5 μm; 5-55% MeCN / water (+NH4OH)) to give 4-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol (16 mg, 44%) as a white solid. LCMS m / z=447.1 [M+H] + , t R =0.56min.
[0520] Example 18: 4-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol
[0521]
[0522] The title compound (7.1 mg, 18%) was prepared as a white solid from 1,6-dioxaspiro[2.5]octane and (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4) using a procedure similar to that described in Example 17 to give the desired compound (16 mg, 44%). LCMS m / z=446.8 [M+H] + , t R =0.55min.
[0523] Example 19: 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine
[0524]
[0525] Acetic acid (34 μL, 0.6 mmol) was added to a mixture of tetrahydropyran-4-ylmethylamine (28 mg, 0.2 mmol) and 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (intermediate 5, 66 mg, 0.2 mmol) in DCM (3 mL). NaBH(OAc) (170 mg, 0.8 mmol) was added to the above solution at once, and the mixture was stirred at room temperature overnight. The reactant was quenched with NH4Cl saturated aqueous solution and stirred at room temperature for 5 min. The mixture was diluted with DCM and saturated NaHCO3 aqueous solution and then stirred for another 5 min. The organic phase was washed with water and evaporated to dryness in vacuo. The residue was dissolved in DMSO and purified by preparative HPLC (Waters Xselect CSH Prep C18 30 x 100 mm, 5 μm; 5-70% MeCN / water (+NH4OH)) to give 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (24 mg, 28%) as a white solid. LCMS m / z = 431.2 [M+H] + , t R =0.58min.
[0526] Examples 20 and 21: (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane and (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0527]
[0528] 1. Synthesis of 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0529]
[0530] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and 4-methylpiperidine using a method similar to that described in Example 19. Purification by preparative HPLC (Waters SunFire C18 19*100 5mkm column; water-ACN-FA 0.1% gradient mixture as mobile phase) gave the title compound (91 mg, 30%). LCMS m / z=415.2 [M+H] + .
[0531] 2. Chiral Separation of 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane
[0532]
[0533] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (60 mg) was separated into its stereoisomers using CHIRALPAK AD-H 4.6 x 150 mm, 5 μm, 30% MeOH w / 0.1% DEA in CO (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40° C.) to give two stereoisomers:
[0534] Peak 1, Example 20, (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (31 mg, tR =2.01 min, 99.9% ee). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.01-7.91 (m, 2H), 7.32 (d, J = 8.8Hz, 2H), 7.26-6.75 (m, 1H), 4.31 (br s, 2H), 2.90 (br d,J=11.2Hz,2H),2.76-2.61(m,1H),2.12(br t,J=11.6Hz,2H),1.96-1.84(m,2H),1.78-1.49(m,8H),1.38(br s,1H),1.27-1.12(m,2H),0.94(d,J=6.4Hz,3H). LCMS m / z=415.2[M+H] +
[0535] Peak 2, Example 21, (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (4 mg, tR =2.32 min, 89.2% ee). 1 H NMR (400MHz, CD3OD) δ (ppm): 7.99-7.83 (m, 2H), 7.32 (d, J = 8.8Hz, 2H), 7.25-6.80 (m, 1H), 4.25 (br s, 2H), 3.00 (br d, J = 9.4Hz, 2H), 2.47 (br s,1H),2.36-2.22(m,2H),1.95(br s,2H),1.74-1.51(m,8H),1.44-1.29(m,1H),1.25-1.12(m,2H),0.93(d,J=6.4Hz,3H). LCMS m / z=415.2[M+H] +
[0536] Examples 22 and 23: 6-((1R, 3s, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.3]heptane and 6-((1R, 3r, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.3]heptane
[0537]
[0538] *Stereochemistry arbitrarily specified
[0539] 6-((1R,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-2-oxa-6-azaspiro[3.3]heptane was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and 2-oxa-6-azaspiro[3.3]heptane using a method similar to that described in Example 19. Purification by column chromatography (24 g SiO, 20-50-100% EtOAc / EtOH (3 / 1) in heptane) gave:
[0540] * Peak 1, Example 22; white solid (42 mg, 49%). 1H NMR (400MHz, CD3OD) δ (ppm): 8.50 (d, J = 8.3Hz, 1H), 7.81 (d, J = 8.0Hz, 1H), 4.69 (s, 4H), 4.09 (dd, J = 4.4, 2.9Hz, 2H), 3.21 (s, 4H), 2.88 (s, 3H), 2.35 (t, J = 5.6Hz, 1H), 2.16–2.05 (m, 2H), 1.89–1.74 (m, 4H), 1.69–1.60 (m, 2H). LCMS m / z=432.2[M+H] + .
[0541] * Peak 2, Example 23; oil (6 mg, 6%). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.61–8.43 (m, 1H), 7.81 (d, J = 8.0Hz, 1H), 4.69 (s, 4H), 4.28–4.20 (m, 2H), 3.34(s,4H),2.89(s,3H),2.59–2.45(m,1H),2.05–1.93(m,2H),1.87–1.73(m,4H),1.38–1.26(m,2H). LCMS m / z=432.1[M+H] + .
[0542] Examples 24 and 25: (1R, 3s, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine and (1R, 3r, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine
[0543]
[0544] *Stereochemistry arbitrarily specified
[0545] (1R,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and tetrahydropyran-4-ylmethanamine using a method similar to that described in Example 19. Purification by column chromatography (24 g SiO2, 20-100% EtOAc / EtOH (3 / 1) in heptane) gave:
[0546] * Peak 1, Example 24: white solid (56 mg, 63%). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.57–8.46 (m, 1H), 7.82 (d, J = 8.0Hz, 1H), 4.15 (br d,J=2.8Hz,2H),3.99–3.87(m,2H),3.40(td,J=11.7,1.9Hz,2H),2.96–2.84(m,4H),2.43(d,J=6.3Hz ,2H),2.28–2.19(m,2H),2.10–1.96(m,2H),1.94–1.82(m,2H),1.79–1.55(m,5H),1.37–1.17(m,2H). LCMS m / z=448.2[M+H] + .
[0547] * Peak 2, Example 25: oil (5.5 mg, 6%). 1 H NMR(400MHz, CD3OD)δ(ppm):8.53(d,J=8.3Hz,1H),7.82(d,J=8.0Hz,1H),4.35–4.20(m,2H),3.98–3.85(m,2H),3.39(td,J =11.8,2.0Hz,2H),2.92(s,4H),2.45(d,J=6.3Hz,2H),2.07–1.93(m,4H),1.81(d,J=7.5Hz,2H),1.70–1.61(m,3H),1.48(br s,2H),1.27–1.18(m,2H). LCMS m / z=448.1[M+H] + .
[0548] Examples 26 and 27: (1R, 3s, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine and (1R, 3r, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine
[0549]
[0550] *Stereochemistry arbitrarily specified
[0551] (1R,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and (3-methyloxetan-3-yl)methanamine using a method similar to that described in Example 19. Purification by column chromatography (24 g SiO2, 20-100% EtOAc / EtOH (3 / 1) in heptane) gave:
[0552] * Peak 1, Example 26: white solid (46 mg, 53%). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.52 (d, J = 8.0Hz, 1H), 7.82 (d, J = 8.3Hz, 1H), 4.48 (d, J = 5.8Hz, 2H), 4.34 (d, J = 5.5Hz, 2H ),4.20–4.10(m,2H),2.90(s,4H),2.72(s,2H),2.30–2.19(m,2H),2.08–1.96(m,2H),1.93–1.74(m,4H),1.31(s,3H). LCMS m / z=434.2[M+H] + .
[0553] * Peak 2, Example 27: white solid (6 mg, 7%). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.57–8.49 (m, 1H), 7.82 (d, J = 8.0Hz, 1H), 4.42 (d, J = 5.8Hz, 2H), 4.32 (d, J = 5.8Hz, 2H), 4.27 (br dd,J=4.1,2.9Hz,2H),3.00–2.88(m,4H),2.77(s,2H),2.06–1.95(m,4H),1.86–1.78(m,2H),1.56–1.43(m,2H),1.28(s,3H). LCMS m / z=434.2[M+H] + .
[0554] Example 28: (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]oct-3-amine
[0555]
[0556] To a mixture of (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (intermediate 4, 45 g, 0.1 mmol) and 3-methyloxetane-3-carbaldehyde (14 mg, 0.1 mmol) in DCM (3 mL) was added acetic acid (17 μL, 0.3 mmol). NaBH(OAc) (85 mg, 0.4 mmol) was added once and the mixture was stirred at room temperature overnight. The reactant was quenched with saturated NH4Cl aqueous solution, and the mixture was stirred at room temperature for 5 min. Additional DCM and saturated NaHCO3 were added, and the reaction mixture was stirred for another 5 min. The organic phase was washed with water and then evaporated to dryness in a vacuum. The residue was dissolved in DMSO and purified by preparative HPLC (Waters Xselect CSH PrepC18 30 x 100mm, 5 μm; 5-55% MeCN / water (+NH4OH)) to give (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (27 mg, 64%) as a white solid. LCMS m / z = 417.1 [M+H] + , t R =0.57min.
[0557] Example 29: (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine
[0558]
[0559] Acetic acid (21 μL, 0.4 mmol) and NaBH(OAc) (105 mg, 0.5 mmol) were added to a mixture of (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine trifluoroacetate (intermediate 4, 55 mg, 0.1 mmol) and tetrahydropyran-4-carbaldehyde (15.5 mg, 0.1 mmol) in DCM (2 mL), and the mixture was stirred at room temperature for 2 h. The reactants were quenched with saturated NaHCO aqueous solution, diluted with DCM and stirred for 5 min. The organic phase was washed with water, dried (MgSO) and evaporated to dryness in vacuo. The residue was purified by column chromatography (12 g SiO2, EtOAc / EtOH 3 / 1) to give (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (32 mg, 60%) as a white solid. 1 H NMR (400MHz, CD3OD) δ (ppm): 8.01–7.89 (m, 2H), 7.32 (d, J = 8.5Hz, 2H), 7.23–6.78 (m, 1H), 4.29 (br s, 2H), 3.94 (br dd,J=11.4,4.1Hz,2H),3.42(t,J=11.7Hz,2H),2.91(dt,J=11.2,5.6Hz,1H),2 .46(d,J=6.5Hz,2H),2.09–1.94(m,2H),1.79–1.45(m,9H),1.38–1.15(m,2H). LCMSm / z=431.2[M+H] + .
[0560] Example 30: 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0561]
[0562] DIPEA (70 μ L, 0.4 mmol) is added to a mixture of 1-methyl-2-oxabicyclo [2.1.1] hexan-4-amine HCl salt (36 mg, 0.2 mmol) and 8-[4-(difluoromethoxy)phenyl]sulfonyl-8-azabicyclo [3.2.1] octan-3-one (66 mg, 0.2 mmol) in DCM (3 mL). NaBH (OAc) (170 mg, 0.8 mmol) is added to the above solution once, and the mixture is stirred at room temperature overnight. Additional NaBH (OAc) (85 mg, 0.4 mmol) is added and stirring is continued at room temperature overnight. The reactant is quenched with saturated NH4Cl aqueous solution and stirred at room temperature for 5 min. The reaction mixture is diluted with DCM and saturated NaHCO3 aqueous solution and stirred for 5 min. The organic phase is washed with water and concentrated. The residue was dissolved in DMSO and purified by preparative HPLC (Waters Xselect CSH Prep C18 30 x 100 mm, 5 μm; 5-70% MeCN / water (+ NH4OH)) to give 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (20 mg, 23%) as a white solid. LCMS m / z=429.1 [M+H] + , t R =0.60min.
[0563] Example 31: (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]oct-3-amine
[0564]
[0565] (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine (23.8 mg, 59%) as a white solid was prepared from (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4) and oxetane-3-carbaldehyde using a method similar to that described in Example 28 to give the desired compound (31 mg, 76%). LCMS m / z=402.9 [M+H] + , t R =0.56min.
[0566] Example 32: (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]oct-3-amine
[0567]
[0568] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (35 mg, 75%) was prepared from (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3) and tetrahydro-2H-pyran-4-carbaldehyde using a method similar to that described in Example 28. LCMS m / z = 431.2 [M+H] + , t R =0.59min.
[0569] Example 33: (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol
[0570]
[0571] 1. Synthesis of tert-butyl (1R,3r,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2'-oxirane]-8-carboxylate
[0572]
[0573] Before adding a solution of (1R, 5S)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (2g, 8.9mmol) in DMSO (5mL), trimethylsulfoxide iodide (2.93g, 13.32mmol) was added to a suspension of NaH (533mg, 13.3mmol, 60% purity) in DMSO (5mL) and stirred at 25°C for 1h under N2. After the starting material was consumed, water (20mL) was added and the resulting mixture was extracted with DCM (3x 50mL). The combined organics were washed with brine (20mL), dried (Na2SO4) and evaporated to dryness in vacuo. The residue was purified by column chromatography (SiO2, 0-17% EtOAc / PE) to give compound (1R,3r,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2'-oxirane]-8-carboxylic acid tert-butyl ester (1.5 g, 71%) as a colorless oil. LCMS m / z=183.9 [M-t- Bu+H] + .
[0574] 2. Synthesis of tert-butyl (1R, 3r, 5S)-3-hydroxy-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0575]
[0576] Morpholine (145 μL, 1.7 mmol) was added to a solution of tert-butyl (1R, 3r, 5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2'-oxirane]-8-carboxylate (200 mg, 0.8 mmol) in EtOH (5 mL), and the resulting mixture was stirred at 25° C. for 1 h under N2, and then at 100° C. for another 15 h. The reaction mixture was evaporated to dryness in vacuo, and the residue was purified by column chromatography ( 12g Silica flash column, 30-90% EtOAc / PE) was purified to give (1R,3r,5S)-tert-butyl 3-hydroxy-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (130 mg, 48%) as a colorless oil. LCMS m / z = 327.1 [M+H] + .
[0577] 3. Synthesis of (1R,3r,5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol trifluoroacetate
[0578]
[0579] TFA (2.98 g, 26.1 mmol, 2.00 mL) was added to a solution of compound (1R, 3r, 5S)-3-hydroxy-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (130 mg, 0.4 mmol) in DCM (10 mL), and the mixture was stirred under N2 at 25 °C for 0.5 h. The reaction mixture was evaporated to dryness in vacuo to give (1R, 3r, 5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol trifluoroacetate (150 mg, crude) as a yellow oil, which was used without further purification. 1 H NMR (400MHz, CD3OD) δ (ppm): 3.58 (br s, 2H), 3.18 (s, 4H), 2.54–2.46 (m, 4H), 2.16–2.13 (m, 6H), 2.11–2.06 (m, 4H).
[0580] 4. Synthesis of (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol
[0581]
[0582] 4-(Difluoromethoxy)benzenesulfonyl chloride (100 mg, 0.4 mmol) is added to a solution of (1R, 3r, 5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol trifluoroacetate (100 mg, 0.4 mmol) and DIPEA (340 μL, 1.9 mmol) in DCM (20 mL) at 0 ° C, and the resulting mixture is stirred at 25 ° C for 1 h under N2. Water (10 mL) is added to the reaction mixture and the reaction mixture is extracted with DCM (3 x 30 mL). The combined organic matter is washed with brine (20 mL), dried (Na2SO4) and evaporated to dryness in a vacuum. The residue was purified by preparative HPLC (Welch Xtimate C18 25 x 150 mm, 5 mm; 50-80% MeCN / water (10 mM NH4HCO3)) to give (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol (80 mg, 49%) as a white solid. 1 H NMR (400MHz, CD3OD) δ (ppm): 7.92 (d, J = 8.8Hz, 2H), 7.29 (d, J = 8.4Hz, 2H), 7.00 (t, J = 73.2Hz, 1H), 4.21 (br s,2H),3.67–3.63(m,4H),2.55–2.52(m,4H),2.14–2.08(m,4H),1.89–1.84(m,2H),1.76–1.72(m,2H),1.42–1.40(m,2H). LCMS m / z(ESI):433.1[M+H] + .
[0583] Example 34: (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol
[0584]
[0585] 1. Synthesis of tert-butyl (1R,5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylate
[0586]
[0587] Methyl (triphenyl) phosphine bromide (55.50 g, 155.4 mmol) was added to a solution of potassium tert-butoxide (1 M, 155.4 mL) in THF (40 mL) at 0 ° C under N2, and the resulting mixture was stirred at 0 ° C for 15 min, then heated at 80 ° C for 1 h. The reaction mixture was cooled to room temperature, a solution of (1S, 5R)-3-oxo-8-azabicyclo [3.2.1] octane-8-carboxylic acid tert-butyl ester (7 g, 31.1 mmol) in THF (60 mL) was added dropwise, and stirred at 25 ° C for 15 h. The reaction mixture was diluted with acetone (30 mL) and the resulting solid was removed by filtration. The filtrate was diluted with water (80 mL) and extracted with EtOAc (3 x 100 mL). The combined organic matter was washed with brine (50 mL), dried (Na2SO4) and evaporated to dryness in a vacuum. The residue was purified by column chromatography ( 330g Silica flash column, 5-20% EtOAc / PE gradient eluent) to give (1R,5S)-tert-butyl 3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylate (5 g, 72%) as a colorless oil. LCMS m / z (ESI): 168.1 [M- t- Bu+H] + .
[0588] 2. Synthesis of (1R,3r,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2'-oxirane]-8-carboxylic acid tert-butyl ester and (1R,3s,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2'-oxirane]-8-carboxylic acid tert-butyl ester
[0589]
[0590] 3-Chlorobenzene peroxyformic acid (22.7 g, 112 mmol, 85% purity) was added to a solution of (1R, 5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (10 g, 44.8 mmol) in DCM (100 mL) at 0 ° C. The reaction mixture was stirred at 25 ° C for 24 h before adding additional 3-chlorobenzene peroxyformic acid (9.09 g, 44.8 mmol, 85% purity), and stirring was continued at 25 ° C for 24 h. The resulting solid was removed by filtration and saturated NaHCO3 aqueous solution (50 mL) was added to the filtrate. The aqueous phase was extracted with DCM (3x 80 mL). The combined organics were washed with saturated Na2SO3 aqueous solution (50 mL), brine (20 mL), dried (Na2SO4), filtered and evaporated to dryness in vacuo. The residue was purified by column chromatography ( 120g Purification on silica flash column, 15-35% EtOAc / PE) gave:
[0591] Peak 1: white solid (1R, 3s, 5S)-tert-butyl 8-azaspiro[bicyclo[3.2.1]octane-3,2′-oxirane]-8-carboxylate (2.5 g, 23%). 1 H NMR (400MHz, CDCl3) δ (ppm): 4.29 (br s, 2H), 2.72 (s, 2H), 2.32–2.11 (m, 2H), 2.02–1.92 (m, 2H), 1.72 (br d, J = 7.6Hz, 2H), 1.50–1.42 (m, 9H), 1.25 (br d,J=7.2Hz,2H). LCMS m / z(ESI):140.1[M-Boc+H] + .
[0592] Peak 2: tert-butyl (1R, 3r, 5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2′-oxirane]-8-carboxylate (4.5 g, 42%). 1 H NMR (400MHz, CDCl3) δ (ppm): 4.42–4.19 (m, 2H), 2.48–2.19 (m, 4H), 2.10–1.96 (m, 4H), 1.46 (s, 9H), 1.17 (br d, J = 14.0Hz, 2H).
[0593] 3. Synthesis of tert-butyl (1R, 3s, 5S)-3-(aminomethyl)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate
[0594]
[0595] A mixture of tert-butyl (1R,3s,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2'-oxirane]-8-carboxylate (1 g, 4.2 mmol) and ammonia (7M, 13.3 mL) in water was heated in an autoclave at 60° C. for 96 h. The mixture was concentrated under reduced pressure to give tert-butyl (1R,3s,5S)-3-(aminomethyl)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate (1 g, crude) as a yellow oil which was used without further purification. 1H NMR (400MHz, CD3OD) δ (ppm): 4.35–4.21 (m, 2H), 2.76 (s, 2H), 2.10–1.93 (m, 4H), 1.81 (br d, J = 7.2Hz, 2H), 1.47 (s, 9H), 1.29 (br d, J = 12.4Hz, 2H). LCMS m / z(ESI):201.1[M- t Bu+H] + .
[0596] 4. Synthesis of tert-butyl (1R, 3s, 5S)-3-hydroxy-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0597]
[0598] Under N2, bis(4-methylbenzenesulfonic acid)oxybis(ethane-2,1-diyl)ester (2.91 g, 7.0 mmol) was added to a mixture of (1R, 3s, 5S)-3-(aminomethyl)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (1.2 g, 4.7 mmol) and K2CO3 (1.94 g, 14.0 mmol) in MeCN (30 mL), and the mixture was stirred at 80°C for 15 h. The solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography ( 20g Silica flash column; 0-10% MeOH / DCM) followed by preparative HPLC (YMC-ActusTriart C18 150 x 30 mm, 5 μm, 4-60% MeCN / water (0.05% NH4OH)) to give tert-butyl (1R,3s,5S)-3-hydroxy-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (22 mg, 1.44%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 4.27 (s, 1H), 4.00 (br s, 2H), 3.56 (br t, J = 4.0Hz, 4H), 3.44–3.38 (m, 4H), 2.36 (s, 2H), 1.96 (br s, 2H), 1.80 (br s,2H),1.71–1.54(m,4H),1.41(s,9H). LCMS m / z(ESI):327.2[M+H] + .
[0599] 5. Synthesis of (1R,3s,5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride
[0600]
[0601] HCl / dioxane (4M, 2 mL) was added to a solution of (1R, 3s, 5S)-3-hydroxy-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (25 mg, 0.1 mmol) in MeOH (2 mL), and the resulting mixture was stirred at 20° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give (1R, 3s, 5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride (35 mg) as a yellow oil, which was used without further purification. LCMS m / z (ESI): 227.1 [M+H] + .
[0602] 6. Synthesis of (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol
[0603]
[0604] DIPEA (60 μL, 0.3 mmol) and 4-(difluoromethoxy)benzenesulfonyl chloride (41.6 mg, 0.2 mmol) were added to a solution of compound (1R, 3s, 5S)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride (30 mg, 0.1 mmol) in DCM (3 mL) at 0 °C. The resulting mixture was stirred at 20 °C for 3 h and quenched with water (10 mL). The reaction mixture was extracted with DCM (3 x 10 mL) and the combined organic layer was washed with brine (3 x 10 mL), dried (Na2SO4), filtered and evaporated to dryness in a vacuum. The residue was purified by preparative HPLC (Welch Xtimate C18 25x150 mm, 5 μm; 33-63% MeCN / water (10 mM NH4HCO3)) to give (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol (14.5 mg, 29%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ (ppm): 7.90 (d, J=8.8Hz, 2H), 7.39–7.08 (m, 3H), 4.40 (s, 1H), 4.13 (br s,2H),3.50(d,J=4.2Hz,2H),2.43–2.40(m,6H),2.22(s,2H),2.07(d,J=14.4H z,2H),1.72(dd,J=4.0,13.2Hz,2H),1.44(d,J=8.0Hz,2H),1.26–1.12(m,2H). LCMSm / z(ESI):433.1[M+H] + .
[0605] Example 35: 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)-2,6-difluorophenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0606]
[0607] DIPEA (70 μL, 0.4 mmol) was added to a mixture of 4-(((1R, 3s, 5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine dihydrochloride (intermediate 7, 31 mg, 0.1 mmol) and 4-(difluoromethoxy)-2,6-difluorobenzenesulfonyl chloride (28 mg, 0.1 mmol) in DCM (2 mL), and the mixture was stirred at room temperature for 2 h. The reactant was quenched with saturated NaHCO3 aqueous solution, diluted with water and stirred at room temperature for 5 min. The organic phase was washed with water and evaporated to dryness in vacuo. The residue was ground with a small amount of MeCN to give 4-(((1R, 3s, 5S)-8-((4-(difluoromethoxy)-2,6-difluorophenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine (22 mg, 48%) as a white solid. 1 HNMR(400MHz,CD3OD)δ(ppm):7.33–6.81(m,3H),4.33(br d,J=2.3Hz,2H),3.79–3.59(m,4H),2.50–2.31(m,4H),2.20–2.03(m,3H),1.82–1.66(m,6H),1.45–1.34(m,2H). LCMS m / z=453.1[M+H] + .
[0608] Example 36: 4-(((1R,3s,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0609]
[0610] 4-(((1R,3s,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine (43 mg, 90%) as a white solid was prepared from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 2,5-dimethylpyrazole-3-sulfonyl chloride using a method similar to that described in Example 35. Purification by column chromatography (12 g, SiO2, 7:1 EtOAc / EtOH). 1 H NMR (400MHz, CD3OD) δ (ppm): 6.62 (s, 1H), 4.36–4.18 (m, 2H), 4.00 (s, 3H), 3.77–3.62 (m, 4H), 2.51–2 .32(m,4H),2.25(s,3H),2.21–2.15(m,2H),2.15–2.04(m,1H),1.83–1.70(m,6H),1.45–1.34(m,2H). LCMS m / z=369.2[M+H] + .
[0611] Example 37: 4-(((1R,3r,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0612]
[0613] 4-(((1R,3r,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine (29 mg, 70%) as a colorless oil was prepared from 4-(((R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine dihydrochloride (Intermediate 8) and 2,5-dimethylpyrazole-3-sulfonyl chloride using a method similar to that described in Example 35. 1H NMR (400MHz, CD3OD) δ (ppm): 6.60 (s, 1H), 4.30–4.17 (m, 2H), 3.97 (s, 3H), 3.70–3.62 (m, 4H), 2.40 (br d,J=4.5Hz,4H),2.23(s,3H),2.19–2.04(m,3H),1.82–1.67(m,6H),1.44–1.31(m,2H). LCMS m / z=369.2[M+H] + .
[0614] Example 38: 4-(((1R,3s,5S)-8-((3,5-dimethylisoxazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0615]
[0616] 4-(((1R,3r,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine (46 mg, 83%) as a white solid was prepared from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 3,5-dimethylisoxazole-4-sulfonyl chloride using a method similar to that described in Example 35. 1 H NMR(400MHz,CD3OD)δ(ppm):4.26–4.13(m,2H),3.76–3.59(m,4H),2.63(s,3H),2.48–2.28(m,7H),2.18–2.14(m,2H),2.12–1.98(m,1H),1.91 -1.63(m,6H),1.35(s,2H). LCMS m / z=370.2[M+H] + .
[0617] Example 39: 4-(((1R,3s,5S)-8-((4,6-dimethylpyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0618]
[0619] 4-(((1R,3s,5S)-8-((4,6-dimethylpyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine (38 mg, 50%) as a white solid was prepared from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 4,6-dimethylpyridine-3-sulfonyl chloride using a method similar to that described in Example 35. 1 H NMR (400MHz, CD3OD) δ (ppm): 8.82 (s, 1H), 7.34 (s, 1H), 4.17 (br s, 2H), 3.71–3.60 (m, 4H), 2.64 (s, 3H), 2.57 (s, 3H), 2.38 (br s,4H),2.17–2.12(m,2H),2.12–2.04(m,1H),1.97–1.90(m,2H),1.80–1.68(m,4H),1.32(br t,J=10.9Hz,2H). LCMS m / z=380.2[M+H] + .
[0620] Example 59: rac4-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol
[0621]
[0622] 1. Synthesis of tert-butyl (1R, 3r, 5S)-3-(3-hydroxybutyramido)-8-azabicyclo[3.2.1]octane-8-carboxylate
[0623]
[0624] 3-Hydroxybutyric acid (193.20mg, 1.86mmol), (1R, 3r, 5S)-3-amino-8-azabicyclo [3.2.1] octane-8-tert-butyl formate (400mg, 1.77mmol) and NMI (507.90mg, 6.19mmol, 493.11 μL) are combined and dissolved in MeCN (15mL). TCFH (743.87mg, 2.65mmol) is added once and the reaction is monitored by LCMS. After 12h, the mixture is diluted with water (15mL) and extracted with DCM (20mL x 3). The combined organic layer is washed with brine (30mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude mixture is dissolved in MeOH (10mL) and K2CO3 (488.54mg, 3.53mmol) is added. The resulting mixture was stirred at 22 ° C for 1 h, then diluted with water (15 mL), and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column (MeOH / DCM=0%~1%) to obtain the desired compound (380 mg, 69% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δppm6.67 (d, J = 7.2Hz, 1H), 4.21-4.13 (m, 4H), 2.24-2.15 (m, 2H), 2.0 5-2.00(m,4H),1.85-1.80(m,2H),1.70-1.61(m,2H),1.46(s,9H),1.25(d,J=6.0Hz,3H). LCMS m / z=257.1[M+H- t Bu] + .
[0625] 2. Synthesis of N-((1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl)-3-hydroxybutyramide
[0626]
[0627] A solution of tert-butyl (1R,3r,5S)-3-((3-hydroxybutyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (380.00 mg, 1.22 mmol) in HCl / MeOH (4M, 6 mL) was stirred at 20° C. for 1 h. Evaporation in vacuo gave crude N-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3-hydroxybutanamide (300 mg, hydrochloride) as a colorless oil. 1H NMR (400MHz, CD3OD) δppm 4.21-4.09 (m, 1H), 4.05-3.96 (m, 3H), 2.41-2.22 (m, 6H), 2.17-2.03 (m, 4H), 1.22 (d, J = 6.0Hz, 3H). LCMS m / z=212.9[M+H] + .
[0628] 3. Synthesis of N-((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-3-hydroxybutanamide
[0629]
[0630] 4-(Difluoromethoxy)benzenesulfonyl chloride (438.93 mg, 1.81 mmol, 288.20 μL) was added to a solution of 4-(((1R, 3r, 5S)-8-azabicyclo[3.2.1]octan-3-yl)amino)butan-2-ol (300.00 mg, 1.21 mmol, hydrochloride) and DIPEA (623.47 mg, 4.82 mmol, 840.26 μL) in DCM (6 mL) at 0-5 °C. The mixture was stirred at 20 °C for 2 h. The mixture was diluted with water (15 mL) and extracted with DCM (20 mL x 3). The combined organic layers were washed with brine (40 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column (MeOH / DCM = 0.5% - 2%) to afford the desired compound (320 mg, 63% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δppm 7.91-7.85(m,2H),7.25-7.17(m,2H),6.80-6.40(m,2H),4.24(br s,2H),4.19-4.08(m,2H),2.94(br s,1H),2.37-2.18(m,4H),1.85-1.72(m,6H),1.22(d,J=6.0Hz,3H). LCMS m / z=419.0[M+H] + .
[0631] 4. Synthesis of rac-4-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol
[0632]
[0633] BH3·DMS (10M, 95.59 μL) was added to a solution of N-((1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-3-hydroxybutanamide (100 mg, 238.97 μmol) in THF (8 mL) at 20° C., and the reaction mixture was stirred at 70° C. for 1 h under nitrogen. The mixture was quenched with methanol (10 mL) at 20° C. and then heated at 70° C. for 0.5 h. Concentration in vacuo gave the crude product, which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um, conditions: water (0.05% ammonium hydroxide v / v)-ACN, 50% to 80%, flow rate (ml / min): 30)) to give the title compound (111 mg, 37% yield) as a white solid. 1 HNMR(400MHz,CD3OD)δppm 7.94-7.89(m,2H),7.32-7.26(m,2H),7.00(t,J=73.2Hz,1H),4.17(br s,2H),3.90-3.80(m,1H),2.89-2.81(m,1H),2.66(t,J=6.4Hz,2H),2.18-2.03(m,2H),1.97- 1.86(m,2H),1.79-1.69(m,2H),1.64-1.48(m,2H),1.47-1.41(m,2H),1.14(d,J=6.0Hz,3H). LCMS m / z=405.1[M+H] + .
[0634] Example 60: rac-4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol
[0635]
[0636] Rac-4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)butan-2-ol (200 mg, 42%) as a white solid was prepared using tert-butyl (1R,3s,5S)-3-(3-hydroxybutyramido)-8-azabicyclo[3.2.1]octane-8-carboxylate and 3-hydroxybutyric acid from step 1 following a procedure similar to that described in Example 59. 1H NMR (400MHz, methanol-d4) δ = 7.99-7.95 (m, 2H), 7.34 (d, J = 8.8Hz, 2H), 7.24-6.86 (m, 1H), 4.41 (br s,2H),3.93-3.84(m,1H),3.60-3.47(m,1H),3.16-3.09(m,2H),2.19-2.14(m,2H ),1.86-1.78(m,3H),1.72-1.64(m,3H),1.58-1.52(m,2H),1.23(d,J=6.4Hz,3H). LCMS m / z=405.2[M+H] + .
[0637] Examples 61 and 62: (1R,3r)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol and (1R,3r)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol
[0638]
[0639] *Stereochemistry arbitrarily specified
[0640] (1R,3r)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol and (1R,3r)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol were prepared according to general procedure C using (1r,3r)-3-(aminomethyl)cyclobutan-1-ol (HCl salt) as secondary amine. The crude reaction mixture was separated by SFC (column: DAICEL CHIRA LPAK AS (250mm*50mm, 10um); condition: 0.1% NH3H2O ETOH; Start B: 40%; End B: 40%; Flow rate (ml / min): 200) to give (1R,3r)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol (233.15 mg, 23% yield) and the crude (1R,3r)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol was further purified by preparative HPLC (column: Boston Green ODS150*30mm*5um; Conditions: water (HCl)-CAN; Start B: 20; End B: 40; Flow rate (ml / min): 25) to give the second isomer (200 mg, 20% yield) as a white solid.
[0641] *Peak 1, Example 61: 1 H NMR (400MHz, CD3OD) δppm 7.91 (d, J=8.8Hz, 2H), 7.31-7.27 (m, 2H), 7.01 (t, J=72.8Hz, 1H), 4.32-4.24 (m, 1H), 4.17 (br s,2H),2.91-2.87(m,1H),2.57(d,J=7.6Hz,2H),2.11-2.07(m,1H),2.06-1.97(m,8H),1.73-1.68(m,2H),1.44-1.41(m,2H). LCMS m / z=417.1[M+H] + .
[0642] *Peak 2, Example 62: 1H NMR(400MHz,CD3OD)δppm 7.95(d,J=8.8Hz,2H),7.32(d,J=8.8Hz,2H),7.03(t,J=72.8Hz,1H),4.43-4.30(m,3H),3.51(m,1H) ,3.08(d,J=8.0Hz,2H),2.59-2.45(m,1H),2.22-2.10(m,6H),1.89-1.75(m,2H),1.69-1.51(m,4H). LCMS m / z=417.1[M+H] + .
[0643] Examples 63 and 64: (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol and (1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol
[0644]
[0645] *Stereochemistry arbitrarily specified
[0646] (1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol and (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol were prepared according to General Procedure C using (1s,3r)-3-(aminomethyl)cyclobutan-1-ol (HCl salt) as the secondary amine. The crude reaction mixture was purified by flash silica gel chromatography (DCM / MeOH=10 / 1) to give a mixture of isomers as a white solid. The product was then purified by SFC (column DAICEL CHIRALPAK IG (250mm*30mm,10um); condition: 0.1% NH3.H2OMEOH; start B: 45%; end B: 45%; flow rate (ml / min): 80) to separate the isomers to give (1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol (75.75mg 6% yield) as a white solid and (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol (237.56mg, 19% yield) as a white solid.
[0647] *Peak 1, Example 63: 1 H NMR(500MHz,DMSO-d6)δppm 7.95-7.84(m,2H),7.55-7.23(m,3H),4.88-4.88(m,1H),4.16(br s,2H),4.18-4.13(m,1H),3.91-3.74(m,1H),2.46-2.42(m,2H),2.24-2.16(m,2H),1.88-1. 80(m,2H),1.75-1.60(m,1H),1.52-1.44(m,2H),1.40-1.37(m,2H),1.32-1.15(m,5H).LCMS m / z=417.1[M+H] + .
[0648] *Peak 2, Example 64: 1H NMR 500MHz, DMSO-d6)δppm 7.92-7.87(m,2H),7.56-7.19(m,3H),4.85(d,J=6.5Hz,1H),4.08(br s,2H),3.90-3.83(m,1H),2.79(t,J=5.5Hz,1H),2.42-2.40(m,2H),2.24-2.16(m,2H) ,1.98-1.92(m,2H),1.86-1.80(m,2H),1.73-1.66(m,3H),1.43-1.34(m,2H),1.28(br s,1H),1.23-1.15(m,2H). LCMS m / z=417.1[M+H] + .
[0649] Example 65: (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0650]
[0651] 1. Synthesis of (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]oct-3-amine
[0652]
[0653] (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3, 100 mg, 0.3 mmol) and tetrahydro-4H-pyran-4-one (36 μL, 0.4 mmol) in the form of hydrochloride were dissolved in DCM (2 mL). To this was added DIPEA (160 μL, 0.9 mmol) under stirring. After 10 min, acetic acid (52 μL, 0.9 mmol) was added under stirring. After 10 min, sodium triacetoxyborohydride (255 mg, 1.2 mmol) was added under stirring. Additional DCM (2 mL) was added, and the reaction was stirred overnight at room temperature. The reaction mixture was poured into saturated sodium bicarbonate, extracted with ethyl acetate, and the organics were evaporated. The residue was purified by silica gel chromatography using 0-100% 3:1 ethyl acetate / ethanol (+2% NH4OH) in heptane as eluent to give (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (117 mg, 93%).1 H NMR(400MHz,CD3OD)δ(ppm):7.85-7.99(m,2H),7.26-7.33(m,2H),6.79-7.21(m,1H),4.21( dt,J=4.83,2.48Hz,2H),3.93(dt,J=10.10,2.10Hz,2H),3.40(td,J=11.86,2.13Hz,2H),3.1 8(tt,J=6.65,3.51Hz,1H),2.81(tt,J=10.95,4.11Hz,1H),2.21(dt,J=13.68,5.96Hz,2H),1 .91-1.97(m,3H),1.78-1.85(m,2H),1.57-1.65(m,2H),1.41-1.52(m,2H)1.25-1.38(m,1H). LCMS m / z=417.2[M+H] + .
[0654] 2. Synthesis of (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]oct-3-amine
[0655]
[0656] (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (40 mg, 0.1 mmol) was dissolved in DMF (1 mL). To this was added sodium hydride (60% purity, 8 mg, 0.2 mmol) followed by iodomethane (24 μL, 0.4 mmol). The reaction was stirred at room temperature for 45 min to 1.5 h. The reaction was quenched by adding saturated sodium bicarbonate solution, extracted with ethyl acetate, and the organics evaporated. The residue was dissolved in DMSO and purified by preparative HPLC (Waters SunFire Prep C18 5 μm OBD 30×100 mm; 5-55% MeCN / water (+TFA)) to give (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (trifluoroacetate) (19 mg, 36%) as a white solid. LCMS m / z=431.3 [M+H] + , t R =1.38min.
[0657] Example 66: (1R, 3s, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0658]
[0659] The title compound (trifluoroacetate salt) (18 mg, 38%, two steps) was prepared as a clear oil from (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4 as the hydrochloride salt) using a procedure similar to that described in Example 65. LCMS m / z = 431.3 [M+H] + , t R =1.39min.
[0660] Example 67: 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine
[0661]
[0662] 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine (48 mg, 89%) as a white solid was prepared from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 4-(difluoromethoxy)benzenesulfonyl chloride using a method similar to that described in Example 35 and purified by preparative HPLC (Welch Xtimate C18 25 x 150 mm, 5 μm; 33-63% MeCN / water (10 mM NH4HCO3) to give the desired compound (48 mg, 89%). LCMS m / z = 417.2 [M+H] + .t R =0.59min.
[0663] Examples 68 and 69: (1R, 3s, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine and (1R, 3r, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0664]
[0665] *Stereochemistry arbitrarily specified
[0666] (1R,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and 2-oxaspiro[3.3]hept-6-amine using a method similar to that described in Example 19 and purified by column chromatography (24 g SiO2, 20-50-100% EtOAc / EtOH (3 / 1) in heptane) to give:
[0667] * Peak 1, Example 68; white solid (35 mg, 36%). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.53 (d, J = 9.0Hz, 1H), 7.84 (d, J = 8.0Hz, 1H), 4.72 (s, 2H), 4.59 (s, 2H), 4.16 (br s,2H),3.05-3.17(m,1H),2.84-2.94(m,4H),2.46-2.57(m,2H),2.12-2.22(m,2H),1.99-2.11(m,2H),1.85-1.97(m,4H),1.65(br d,J=15.0Hz,2H). LCMS m / z=446.2[M+H] + .
[0668] * Peak 2, Example 69; white solid (22 mg, 23%). 1 H NMR (400MHz, CD3OD) δ (ppm): 8.54 (d, J = 8.0Hz, 1H), 7.85 (d, J = 8.0Hz, 1H), 4.21 (br s, 2H), 3.63-3.75 (m, 3H), 2.92 (s, 3H), 2.71-2.78 (m, 1H), 2.59 (br s,2H),2.17-2.23(m,2H),2.04-2.14(m,2H),1.93(dt,J=6.3,3.4Hz,2H),1.86(br s,2H),1.58(br d,J=15.0Hz,2H),1.45(dd,J=5.0,2.0Hz,2H). LCMSm / z=446.2[M+H] + .
[0669] Example 70: 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((R)-tetrahydrofuran-3-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0670]
[0671] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((R)-tetrahydrofuran-3-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and (R)-tetrahydrofuran-3-amine using a method similar to that described in Example 19 and purified by column chromatography (12 g SiO2, 50-100% EtOAc in heptane) to give a white powder after lyophilization (15 mg, 19%). 1 H NMR (400MHz, CD3OD) δ (ppm): 7.86-8.00 (m, 2H), 7.31 (d, J = 8.8Hz, 2H), 6.76-7.24 (m, 1H), 4.19 (br s,2H),3.68-3.97(m,3H),3.37-3.52(m,2H),2.99(br t,J=6.0Hz,1H),1.96-2.21(m,5H),1.60-1.78(m,3H),1.34-1.53(m,2H). LCMS m / z=403.1[M+H] + .
[0672] Example 71: (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-fluorooxetan-3-yl)methyl)-8-azabicyclo[3.2.1]oct-3-amine
[0673]
[0674] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-fluorooxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (stereochemistry arbitrarily assigned) was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and (3-fluorooxetan-3-yl)methanamine using a method similar to that described in Example 19 and purified by column chromatography (12 g SiO2, 20-50-100% EtOAc / EtOH 3 / 1 in heptane) to give a white powder after lyophilization (6.3 mg, 7%, more polar isomer, stereochemistry arbitrarily assigned). LCMS m / z = 421.1 [M+H] +.t R =0.58min.
[0675] Example 72: (1R, 3r, 5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]oct-3-amine
[0676]
[0677] (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3) and oxetane-3-carbaldehyde using a procedure similar to that described in Example 19 and purified by preparative HPLC (Welch Xtimate C18 25 x 150 mm, 5 μm; 33-63% MeCN / water (10 mM NH4HCO3) to give the desired compound (48 mg, 76%). LCMS m / z = 403.1 [M+H] + .t R =0.56min.
[0678] Example 73: 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0679]
[0680] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and tetrahydro-2H-pyran-4-amine using a procedure similar to that described in Example 19 and purified by preparative HPLC (Welch Xtimate C18 25 x 150 mm, 5 μm; 33-63% MeCN / water (10 mM NH4HCO3) to give the desired compound (18 mg, 22%). LCMS m / z=417.2 [M+H] + .t R =0.58min.
[0681] Example 74: 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0682]
[0683] 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and cyclobutanamine using a procedure similar to that described in Example 19 and purified by preparative HPLC (Welch Xtimate C18 25x150mm, 5μm; 33-63% MeCN / water (10mM NH4HCO3) to give the desired compound (61 mg, 67%). LCMS m / z=389.1 [M+H] + .t R =0.55min.
[0684] Example 75: (1R, 3s, 5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine
[0685]
[0686] (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 9) and tetrahydro-4H-pyran-4-one using a method similar to that described in Example 19 and purified by column chromatography (12 g SiO2, 50-100% tOAc / EtOH 3 / 1 in heptane) to give a white sticky solid (65 mg, 63%). 1H NMR (methanol-d4, 400MHz): δ (ppm) 8.55 (d, J = 8.5Hz, 1H), 7.84 (d, J = 8.0Hz, 1H), 4.28 (dd, J = 4.0, 3.0Hz, 2H), 3.94 (dd, J = 11.0, 4.0Hz, 2H), 3.40 (td, J = 12.0, 2.0Hz,2H),3.16(tt,J=11.3,5.5Hz,1H),2.95(s,3H),2.71-2.88(m,1H),1 .94-2.05(m,4H),1.78-1.87(m,4H),1.45-1.55(m,2H),1.30-1.43(m,2H). LCMS m / z=434.2[M+H] + .
[0687] Example 76: 1-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-2-methylpropan-2-ol
[0688]
[0689] 1-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-2-methylpropan-2-ol was prepared from (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4) and 2,2-dimethyloxirane using a method similar to that described in Example 17 and purified by column chromatography (12 g SiO2, 100% EtOAc to 100% EtOAc / EtOH 3 / 1) to give a white powder after lyophilization (30 mg, 74%). 1 H NMR (400MHz, CD3OD) δ (ppm): 7.88-8.05 (m, 2H), 7.33 (d, J = 7.3Hz, 2H), 6.77-7.24 (m, 1H), 4.34 (br s, 2H), 3.07-3.24 (m, 1H), 2.72 (s, 2H), 2.08 (br d,J=13.1Hz,2H),1.45-1.81(m,6H),1.24(d,J=1.0Hz,6H)LCMS m / z=405.1[M+H] + .
[0690] Example 77: 1-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-2-methylpropan-2-ol
[0691]
[0692] 1-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-2-methylpropan-2-ol was prepared from (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3) and 2,2-dimethyloxirane using a method similar to that described in Example 17 and purified by column chromatography (12 g SiO2, 100% EtOAc) to give a white powder (12 mg, 30%) after lyophilization. 1 H NMR (400MHz, CD3OD) δ (ppm): 7.94 (dd, J=8.8, 1.0Hz, 2H), 7.31 (d, J=7.8Hz, 2H), 6.77-7.22 (m, 1H), 4.18 (br s, 2H), 2.89 (br t,J=5.8Hz,1H),2.48(s,2H),1.97-2.17(m,4H),1.76(br d,J=14.1Hz,2H),1.34-1.55(m,2H),1.20(d,J=1.0Hz,6H). LCMS m / z=405.1[M+H] + .
[0693] Determination
[0694] EBP functional assay
[0695] The EBP immunoaffinity (IA) LC-MS assay measures the potency of EBP small molecule inhibitors by quantifying the concentration-dependent changes in enzyme substrates and products using liquid chromatography atmospheric pressure chemical ionization mass spectrometry multiple reaction monitoring mass spectrometry (LC-APCI MRM MS). HEK293T cells were used as a source of EBP enzyme. The enzyme was incubated with small molecule inhibitors at varying concentrations for 30 min. The deuterated form of the EBP substrate, yeast sterol-d5 (Avanti Polar Lipids, catalog number 700068P-1 mg), was then added, and the plate was incubated at 37 ° C for 4 h. Finally, the sterol isomers were extracted and injected into the LC-APCI MRM MS. The MRM transitions used for the quantification of yeast sterol and dihydrocholestenol (substrate and product of the EBP enzymatic reaction, respectively) were 372.3-203.2, CE 30, and DP 80 in positive ion mode. The percentage of yeast sterol-d5 converted to dehydrocholestenol-d5 was used to derive the IC 50Tasin-1 (1′-[(4-methoxyphenyl)sulfonyl]-4-methyl-1,4′-bipiperidine, CAS 792927-06-1) was used as a reference small molecule inhibitor.
[0696]
[0697] The percent conversion versus compound concentration data were fitted to the following 4-parameter logistic model to generate the IC 50 curve:
[0698]
[0699] Example Data
[0700]
[0701] *N / A means >2000 nM; + means equal to or less than 2000 nm and greater than 150 nM; ++ means equal to or greater than 50 nm and less than or equal to 150 nM; +++ means <50 nM.
Claims
1. A compound having formula (I): or a pharmaceutically acceptable salt thereof, wherein: A is CH2 or a bond; R 1 and R 2 Each independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, Het, -Z-Het and -ZC 3-8 Cycloalkyl, wherein the C 1-6 Alkyl, C 3-8 Cycloalkyl and Het are each optionally substituted by one or more R 4 Replace, provided that R 1 and R 2 At least one of is not H; or R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4 substituted 4- to 10-membered heterocyclyl; Z is C optionally substituted by one or more halogen groups 1-4 alkyl; Het is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bicyclic heterocyclyl, each of which is optionally replaced by R 4 replace; R 3 is phenyl, 5 or 6-membered monocyclic heteroaryl or 9 or 10-membered bicyclic heteroaryl, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl and 9 or 10-membered bicyclic heteroaryl are each optionally substituted by one or more substituents R 5 replace; R 4 Each occurrence is independently C 1-6 Alkyl, halide and -OR 4a , wherein the C 1-6 The alkyl group is optionally replaced by -OR 4a replace; R 4a H, C 1-6 Alkyl or C 1-6 Haloalkyl; R 5 Each occurrence is independently halo, -OR 5a , C 1-6 Alkyl, C 3-6 cycloalkyl, 4 to 7 membered monocyclic heterocyclyl, 5 to 6 membered monocyclic heteroaryl or phenyl, wherein the C 1-6 Alkyl, C 3-6 The cycloalkyl and 5- to 6-membered monocyclic heteroaryl groups are each optionally substituted with one or more halogen, C 1-4 Alkyl or -OR 5a replace; or two R 5 Together with its intervening atoms, it forms optionally one or more independently selected from C 1-6 Alkyl, oxo, halo, and –OR 5a R 6 substituted 5- to 7-membered heterocyclic ring; R 5a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group; R 7 is H or OR 7a ; R 7a H, H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 Each independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, Het, -Z-Het, wherein the C 1-6 Alkyl, C 3-8 Cycloalkyl and Het are each optionally substituted by one or more R 4 Replace, provided that R 1 and R 2 At least one of is not H; or R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4 substituted 4- to 10-membered heterocyclyl; Z is C optionally substituted by one or more halogen groups 1-4 alkyl; Het is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bicyclic heterocyclyl, each of which is optionally replaced by R 4 replace; R 3 is phenyl, 5 or 6-membered monocyclic heteroaryl or 9 or 10-membered bicyclic heteroaryl, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl and 9 or 10-membered bicyclic heteroaryl are each optionally substituted by one or more substituents R 5 replace; R 4 Each occurrence is independently C 1-6 Alkyl, halide and -OR 4a ; R 4a H, C 1-6 Alkyl or C 1-6 Haloalkyl; R 5 Each occurrence is independently halo, -OR 5a , C 1-6 Alkyl, C 3-6 cycloalkyl, 4 to 7 membered monocyclic heterocyclic group or phenyl, wherein the C 1-6 Alkyl and C 3-6 The cycloalkyl groups are each optionally substituted with one or more halo, -OR 5a replace; or two R 5 Together with its intervening atoms, it forms optionally one or more independently selected from C 1-6 Alkyl, oxo, halo, and –OR 5a R 6 substituted 5- to 7-membered heterocyclic ring; R 5a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group; R 7 is H or OR 7a ; R 7a H, C 1-6 Alkyl or C 1-6 haloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with an alkoxy group.
3. The compound according to claim 1 or 2, wherein the compound is represented by formula II: or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3, wherein the compound is represented by formula (IIA) or (IIB): or a pharmaceutically acceptable salt thereof.
5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, furanyl, oxadiazolyl, imidazopyridinyl, thienyl, thiazolyl, triazolyl and indolyl, each of which is optionally substituted by one to three R 5 replace.
6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, furanyl, oxadiazolyl, imidazopyridinyl, thienyl and indolyl, each of which is optionally substituted by one to three R 5 replace.
7. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 3 It is expressed by the following formula: Each of which is optionally replaced by one to three R 5 Replacement; or R 3 It is expressed by the following formula: Each of which is optionally replaced by one or two R 6 replace.
8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 3 It is expressed by the following formula: Each of which is optionally replaced by one to three R 5 Replacement; or R 3 It is expressed by the following formula: Each of which is optionally replaced by one or two R 6 replace.
9. The compound according to claim 5 or 6 or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl and pyridinyl, each of which is optionally substituted by one to three R 5 replace.
10. The compound according to claim 7 or 8, or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula: Each of which is optionally replaced by one or two R 5 replace; or R 3 It is expressed by the following formula: Each of which is optionally replaced by one or two R 6 replace.
11. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula:
12. The compound according to claim 8 or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula:
13. The compound according to claim 11 or 12, or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula:
14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein R 5 Each occurrence is independently halo, -OR 5a , C 1-6 alkyl, a 4- to 7-membered monocyclic heterocyclic group or a phenyl group, wherein the C 1-6 The alkyl group is optionally replaced by -OR 5a or halogen, and wherein the 5- to 6-membered monocyclic heteroaryl is optionally substituted by C 1-3 Alkyl substituted; and R 6 C 1-3 alkyl.
15. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein R 5 Each occurrence is independently halo, -OR 5a , C 1-6 alkyl, a 4- to 7-membered monocyclic heterocyclic group or a phenyl group, wherein the C 1-6 The alkyl group is optionally replaced by -OR 5a replace.
16. The compound according to claim 14 or a pharmaceutically acceptable salt thereof, wherein R 5 Each occurrence is independently -F, -Cl, -CH3, -CH2CH3, -CF3, -OCHF2, -OCH3, -CH2OCH3, tetrahydropyranyl, phenyl, pyridyl; and R 6 is –CH3, optionally wherein R 5 It is expressed by the following formula:
17. A compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4 Substituted 4- to 9-membered heterocyclyl.
18. A compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a 4- to 6-membered monocyclic saturated heterocyclic group or an 8- to 9-membered bicyclic heterocyclic group, each of which is optionally substituted by one to three R 4 replace.
19. The compound according to claim 18 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula: Each of which is optionally replaced by one to three R 4 replace.
20. The compound according to claim 18 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula: Each of which is optionally replaced by one to three R 4 replace.
21. The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
22. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
23. A compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, wherein: R 1 Het, -C 1-3 Alkyl-Het, -C 1-3 Alkyl-C 3-6 Cycloalkyl, C 3-6 Cycloalkyl or C 1-6 Alkyl, wherein the C 3-6 Cycloalkyl and the C 1-6 The alkyl groups are each optionally substituted by one or two R 4 replace; R 2 H or C 1-3 alkyl; Het is a 4- to 6-membered monocyclic saturated heterocyclic group or a 6- to 7-membered bicyclic saturated heterocyclic group, wherein the 4- to 6-membered monocyclic saturated heterocyclic group and the 6- to 7-membered bicyclic saturated heterocyclic group each contain one oxygen ring atom and are each optionally substituted by one or two R 4 replace; and R 4 Each occurrence is independently –OR 4a , halogen or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally replaced by -OR 4a replace; R 4a H or C 1-3 alkyl.
24. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, wherein: R 1 Het, -C 1-3 Alkyl-Het, C 3-6 Cycloalkyl or C 1-6 Alkyl, wherein the C 3-6 Cycloalkyl and the C 1-6 The alkyl groups are each optionally substituted by one or two R 4 replace; R 2 H or C 1-3 alkyl; Het is a 4- to 6-membered monocyclic saturated heterocyclic group or a 6- to 7-membered bicyclic saturated heterocyclic group, wherein the 4- to 6-membered monocyclic saturated heterocyclic group and the 6- to 7-membered bicyclic saturated heterocyclic group each contain one oxygen ring atom and are each optionally substituted by one or two R 4 replace; and R 4 Each occurrence is independently –OH, halide, or C 1-3 alkyl.
25. The compound of claim 23 or a pharmaceutically acceptable salt thereof, wherein Het is oxetanyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 2-oxaspiro[3.3]heptyl or 5-oxabicyclo[2.1.1]hexyl, each of which is optionally substituted by one R 4 replace.
26. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein Het is oxetanyl, tetrahydro-2H-pyranyl or 5-oxabicyclo[2.1.1]hexyl, each of which is optionally substituted by one R 4 replace.
27. The compound of claim 23 or a pharmaceutically acceptable salt thereof, wherein R 1 It is expressed by the following formula: Each of which is optionally replaced by one or two R 4 replace.
28. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein R 1 It is expressed by the following formula: Each of which is optionally replaced by one or two R 4 replace.
29. The compound of claim 23 or a pharmaceutically acceptable salt thereof, wherein R 1 It is expressed by the following formula:
30. The compound of claim 28 or a pharmaceutically acceptable salt thereof, wherein R 1 It is expressed by the following formula:
31. A compound as described in any one of claims 23 to 30, or a pharmaceutically acceptable salt thereof, wherein R 2 is H or –CH3.
32. A compound as described in any one of claims 23 to 30, or a pharmaceutically acceptable salt thereof, wherein R 2 For H.
33. A compound as described in any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein each R 4 Each occurrence is independently -F, -CH3, -CH2CH2OCH3, -CH2OH, -OH or -OCH3.
34. The compound of claim 3, wherein the compound is of formula (III) or (IV): or a pharmaceutically acceptable salt thereof, wherein: R 1 C 3-6 Cycloalkyl, Het or -CH2-Het, wherein the C 3-6 The cycloalkyl group is optionally substituted with one R 4 replace; Het is a 4- to 6-membered monocyclic saturated heterocyclic group or a 6- to 7-membered bicyclic saturated heterocyclic group, wherein the 4- to 6-membered monocyclic saturated heterocyclic group and the 6- to 7-membered bicyclic saturated heterocyclic group both contain one oxygen ring atom and are each optionally substituted by one R 4 replace; Ring A is a 4- to 6-membered monocyclic saturated heterocyclic group or an 8- or 9-membered bicyclic heterocyclic group, each of which is optionally substituted by one or two R 4 replace; R 3 is phenyl, pyridyl or 5-membered heteroaryl, each of which is optionally substituted by one or two R 5 replace; R 4 Each occurrence is independently selected from -OH, halo and C 1-3 alkyl; R 5 Each occurrence is independently selected from halo, -OR 5a , C 1-6 alkyl, a 4- to 6-membered monocyclic heterocyclic group or a phenyl group, wherein the C 1-6 The alkyl group is optionally substituted with one to three halo or -OR 5a replace; or two R 5 Together with its intervening atoms, it forms optionally one to three independently selected C 1-6 Alkyl, oxo and halogen R 6 a substituted 6-membered heterocyclic ring; and R 5a H, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
35. The compound of claim 34 or a pharmaceutically acceptable salt thereof, wherein: Het is oxetanyl, tetrahydro-2H-pyranyl or 5-oxabicyclo[ 2.1.1] hexyl, each of which is optionally substituted by one R 4 replace; Ring A is Each of which is optionally replaced by one or two R 4 replace; R 3 for Each of which is optionally replaced by one or two R 5 replace; or R 3 for Each of which is optionally replaced by one or two R 6 replace.
36. The compound of claim 35 or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula:
37. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 34 to 36, wherein Het is represented by the following formula:
38. A compound as described in any one of claims 34 to 37, or a pharmaceutically acceptable salt thereof, wherein R 4 Each occurrence is independently -CH3, -OH or F.
39. A compound as described in any one of claims 34 to 38, or a pharmaceutically acceptable salt thereof, wherein R 5 Each occurrence is independently -OCF3, -OCHF2, Cl, -CH2OCH3, -CH3, -CF3, -OCH3, -CH2CH3, 40. The compound of claim 1 or 2, wherein the compound is of formula V: or a pharmaceutically acceptable salt thereof.
41. The compound of claim 40, wherein the compound is of formula (VA) or (VB): or a pharmaceutically acceptable salt thereof.
42. The compound of claim 40 to 41 or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of phenyl, pyrazolyl, isoxazolyl and pyridinyl, each of which is optionally substituted by one to three R 5 replace.
43. A compound as described in any one of claims 40 to 42, or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula: wherein each of the formulae depicted above is optionally replaced by one to three R 5 replace.
44. A compound as described in any one of claims 40 to 43, or a pharmaceutically acceptable salt thereof, wherein R 3 It is expressed by the following formula:
45. A compound as described in any one of claims 40 to 44, or a pharmaceutically acceptable salt thereof, wherein R 5 Each occurrence is independently halo, -OR 5a or C 1-6 alkyl.
46. A compound as described in any one of claims 40 to 45, wherein R 7 is H or OH.
47. A compound as described in any one of claims 40 to 46, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a group represented by the formula:
48. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein the compound is represented by formula (VI) or (VII): or a pharmaceutically acceptable salt thereof, wherein: R 1 C 1-6 Alkyl, C 3-6 Cycloalkyl, Het, -CH2-C 3-4 Cycloalkyl or -CH2-Het, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl and –CH2-C 3-4 The cycloalkyl groups are each optionally substituted by one or two R 4 replace; Het is a 4- to 6-membered monocyclic saturated heterocyclic group containing one oxygen ring atom; Ring A is a 4- to 6-membered monocyclic saturated heterocyclic group or an 8- or 9-membered bicyclic saturated heterocyclic group, each of which is optionally substituted by one or two R 4 replace; R 4 Each occurrence is independently selected from –OR 4a 、-CH2-OR 4a and C 1-3 alkyl; R 4a H or C 1-3 alkyl; R 5 is - OR 5a ; R 5a C 1-3 Halogenated alkyl.
49. The compound of claim 48, or a pharmaceutically acceptable salt thereof, wherein Het is tetrahydropyranyl or oxetanyl.
50. The compound of claim 48 or 49, or a pharmaceutically acceptable salt thereof, wherein R 1 for (i) optionally with one or two R 4 Substituted C 1-6 alkyl; (ii) is represented by the following formula: or (iii) is represented by the following formula: Each of which is optionally replaced by one or two R 4 replace.
51. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein R 1 is –CH(CH3)CH2CH2OCH3 or CH2C(CH3)2OH, or R 1 It is expressed by the following formula:
52. The compound of claim 48 or a pharmaceutically acceptable salt thereof, wherein Ring A is Each of which is optionally replaced by one to two R 4 replace.
53. The compound of claim 52 or a pharmaceutically acceptable salt thereof, wherein Ring A is 54. A compound as described in any one of claims 48 to 53, or a pharmaceutically acceptable salt thereof, wherein each R 4 is independently -OH, -OCH3, -CH2OH or -CH3.
55. A compound as described in any one of claims 48 to 54, or a pharmaceutically acceptable salt thereof, wherein R 5 is –OCHF2.
56. The compound of claim 1, wherein the compound is: 3-Methyl-4-(((1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-1,2,5-oxadiazole; 5-(((1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2-(tetrahydro-2H-pyran-4-yl)oxazole; (1R,3s,5S)-8-((2-methoxy-6-methylpyridin-3-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-8-((4-chloro-1-(methoxymethyl)-1H-pyrazol-5-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; 3,3-Dimethyl-6-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-3,4-dihydroquinolin-2(1H)-one; 5-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2-(tetrahydro-2H-pyran-4-yl)oxazole; (1R,3s,5S)-8-(isochroman-7-ylsulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-8-((5-(methoxymethyl)furan-2-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; 2-methyl-3-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2,4,6,7-tetrahydropyrano[4,3-c]pyrazole; (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-((3-phenyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]octane; 5-methyl-2-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine; (1R,3s,5S)-8-((1,4-dimethyl-1H-pyrazol-5-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-8-((1-ethyl-1H-pyrazol-5-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; 2-((8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)cyclobutan-1-ol; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; 9-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-3,3-difluoro-9-azabicyclo[3.3.1]nonane; 4-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol; 4-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; 6-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.3]heptane; 6-((1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.3]heptane; (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol; (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinylmethyl)-8-azabicyclo[3.2.1]octan-3-ol; 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)-2,6-difluorophenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine; 4-(((1R,3s,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine; 4-(((1R,3r,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine; 4-(((1R,3s,5S)-8-((3,5-dimethylisoxazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine; 4-(((1R,3s,5S)-8-((4,6-dimethylpyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine; (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-((1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-((1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]octane; 4-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-2-(trifluoromethyl)thiazole; (1R,3s,5S)-8-((2,6-difluoro-4-methoxyphenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-((1-phenyl-1H-1,2,3-triazol-4-yl)sulfonyl)-8-azabicyclo[3.2.1]octane; 1,3-Dimethyl-5-(((1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)sulfonyl)-1H-pyrazolo[3,4-b]pyridine; (1R,3s,5S)-8-((3,5-dimethylpyridin-2-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; (1R,3s,5S)-8-((2,6-dimethylpyridin-3-yl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane; 1-((8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)propan-2-ol; 1-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-3-methylpyrrolidin-3-ol; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(3-methoxypyrrolidin-1-yl)-8-azabicyclo[3.2.1]octane; 6-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-oxa-6-azaspiro[3.4]octane; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(4-methoxybutan-2-yl)-8-azabicyclo[3.2.1]octan-3-amine; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8,8'-diaza-3,8'-bis(bicyclo[3.2.1]octane); 8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(3-(2-methoxyethyl)azetidin-1-yl)-8-azabicyclo[3.2.1]octane; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(3-methoxybutan-2-yl)-8-azabicyclo[3.2.1]octan-3-amine; rac-((1R,2S)-2-(((8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclopropyl)methanol; 3-(8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)-3-azabicyclo[3.1.1]heptane; 8'-((4-(difluoromethoxy)phenyl)sulfonyl)-3,8'-diaza-3,3'-bis(bicyclo[3.2.1]octane); rac-4-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol; rac-4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)butan-2-ol; (1R,3r)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol; (1R,3r)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)methyl)cyclobutan-1-ol; (1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol; (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol; (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine; 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)methyl)morpholine; (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine (1R,3r,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]hept-6-yl)-8-azabicyclo[3.2.1]octan-3-amine; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((R)-tetrahydrofuran-3-yl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-fluorooxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine; 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-amine; (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine; 1-(((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-2-methylpropan-2-ol; and 1-(((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]oct-3-yl)amino)-2-methylpropan-2-ol; or a pharmaceutically acceptable salt thereof.
57. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 56 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
58. A method of treating a disease or condition mediated by emopamide binding protein, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 56 or a pharmaceutical composition as claimed in claim 57.
59. A method of treating an autoimmune disease in a subject, comprising administering to the subject an effective amount of a compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 56 or a pharmaceutical composition as described in claim 57.
60. The method of claim 59, wherein the autoimmune disease is multiple sclerosis.
61. The method of claim 60, wherein the compound or pharmaceutical composition repairs myelin sheaths or forms new myelin sheaths in the subject.
62. A method of promoting myelination in a subject suffering from a myelin-related disease or disorder, comprising administering to the subject an effective amount of a compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 56 or a pharmaceutical composition as described in claim 57.
